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Abstract 
 
 It is reported that 13,000 people in the UK are diagnosed with tumours in the 
brain every year, of which 60% are metastatic. Current methods for diagnosing the 
disease can be subjective, invasive and have long diagnostic windows. Raman 
spectroscopy provides a non-destructive, non-invasive, rapid and economical method 
for diagnosis.  
The aim of this study was to assess the use of Raman and immersion Raman 
spectroscopy for diagnosing metastatic brain and glioblastoma multiforme tumours and 
identifying primary sites of origin, and investigate the substrate effect on sample 
preparation and resultant spectra.   
The tissue specimens used in this study were formalin fixed-paraffin preserved 
and were supported on spectroscopic substrates for analysis. Samples were dewaxed 
prior to analysis to reduce/eliminate the paraffin contributions in the Raman spectra. 
The substrate was shown to have a significant influence on this dewaxing procedure and 
thus resulting spectra. It was also observed that specimens on CaF2 and Spectrosil 
quartz retained paraffin after dewaxing, whereas specimens on Low-E substrates did 
not.  
Through data examination, the 721 cm
-1
 and 782 cm
-1
 peaks were identified as 
being the most distinct peaks for discriminating between glioblastoma multiforme, 
metastatic and normal brain tissue spectra. A ratio score plot of these peaks determined 
classification sensitivities and specificities as 100% and 94.44% for glioblastoma 
multiforme, 96.55% and 100% for metastatic brain, and 85.71% and 100% for normal 
brain tissue respectively. Cancerous tissue was observed to retain more wax than normal 
tissue. This difference in dewaxing efficiency was attributed to alterations in tissue 
density between the histological types. Principle component-discriminant function 
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analysis revealed separation between metastatic sites: breast, lung, melanoma, 
colon/rectum and oesophagus and stomach, showing the potential of Raman 
spectroscopy to identify primary sites of origin from metastatic brain tissue.  
 Overall, this study demonstrated the diagnostic ability of Raman spectroscopy 
and the importance of substrate influence on tissue preparation and the quality of 
spectra.  
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Chapter 1  
Introduction 
 
1.1 Metastatic brain cancer 
 
1.1.1 Introduction and epidemiology  
 
 More than one in three people in the UK will develop cancer at some point 
during their lifetime and 50% of these individuals will die from the disease within 5 
years of diagnosis. Cancer is responsible for one in four deaths and in 2010 it was 
estimated that one person died from the disease every 4 minutes [1].  
 
Metastatic brain tumours are intracranial neoplasms that originate from cancers 
located outside the central nervous system (CNS), but have spread there via 
haematogenous routes or invasion from surrounding tissue. Less than 1 in 100,000 
people below 25 years old are reported to have brain metastases, this occurrence 
increases to approximately 30 individuals per 100,000 above the age of 60 [2]. 
Currently, no significant association has been observed between gender and tumour 
incidence [2]. It is estimated that 20–40% of cancer patients develop brain metastases, 
making them the most common form of intracranial neoplasm in adults [3]. 
Approximately, 13,000 people in the UK are diagnosed with tumours of the brain every 
year, of which, 60% are reported to be metastatic tumours [4].  
 
Any malignant tumour has the potential to metastasise to the brain; however, the 
location of the primary tumour is highly dependent on its probability of doing so. Lung 
cancer is the most common primary cancer to metastasise comprising 50% of all brain 
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metastases, breast cancer constitutes 15–25%, and melanoma cancer is responsible for 
5–20% of all metastases, the remaining 5-30% occur as a result of other primary 
cancers. Renal and colon cancers are also known to commonly metastasise to the CNS. 
The primary cancer site is frequently known before the diagnosis of a metastatic brain 
tumour. However, nearly 30% of metastases are detected either before or at the time of 
primary diagnosis [5] and approximately 15% of primary tumour locations remain 
unknown. Identification of the primary tumour significantly increases the efficiency of 
the cancer treatment, and thus patient survival [6].  
 
Over 80% of brain metastases are located in the cerebral hemispheres, due to its 
mass and blood supply [7], roughly 10–15% are situated in the cerebellum and 1–3% 
are found in the brainstem [8]. About 50% of metastatic brain tumours exist as the only 
metastasis in the brain but very rarely do they exist as the only metastasis in the body 
[2]. Breast, colon and renal cancers typically produce only a single metastasis, whereas 
lung and melanoma cancers are often responsible for multiple metastases. Although, 
MRI studies suggest that the number of patients with single metastases is lower than 
previously thought. The number of brain metastases present is important due to the 
influence it has over the selected treatment; and thus all existent metastases should be 
identified [9].  
 
1.1.2 Carcinogenesis 
 
Carcinogenesis is a multistage process whereby cells progress into cancerous 
cells, and is typically divided into three stages: initiation, promotion and progression 
[10]. Figure 1 diagrammatically shows the basic process of carcinogenesis. Initiation 
occurs when exposure to a chemical carcinogen, radiation or other insults results in an 
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interaction with an organism, causing a change to its molecular deoxyribonucleic acid 
(DNA) structure; hence, mutations arise during DNA synthesis.  It causes an 
irreversible increase in the susceptibility of a cell to develop cancer, but does not 
necessarily alter its morphology. Promotion occurs when clonal expansion of the 
initiated cell, due to genetic alteration, results in the formation of a benign tumour.  In 
the progression stage, the benign tumour becomes malignant, invades local tissue and 
has the potential to metastasise. At this point, genetic instability increases and karyotype 
alterations occur [10-12].  
 
Figure 1: The basic process of carcinogenesis. (Adapted from [13]). 
 
 
A stable equilibrium between cell proliferation, growth arrest and 
differentiation, and apoptosis is successfully controlled in normal tissue. Alterations to 
the homeostatic mechanisms that control this stability can result in tumour formation. 
The disparity between cell proliferation and apoptosis causes an increase in tissue mass. 
[11]. Cell proliferation is the production of cells, through replication, needed for normal 
growth and development. The majority of normal human cells have the ability to divide 
once or twice a day, thus replication must be controlled to prevent over-proliferation. 
Differentiation is when cells become specialised and is directly related to a cells ability 
to proliferate. The differentiation of a cell is tightly regulated in normal tissue. 
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Apoptosis refers to cell death and is essential for homeostatic maintenance in normal 
tissue. In neoplastic tissue, the following cellular functions are usually incorrectly 
regulated: cell proliferation is not controlled effectively, cell differentiation is distorted, 
chromosomal and genetic organisation is weakened and apoptosis is inefficiently 
monitored [14]. 
 
Cells that are neoplastic exhibit cytological differences including: increased 
nuclear material, increased nuclear-to-cytoplasmic ratio, increased nuclear staining, 
abnormal nuclear shape and size, abnormal chromatin distribution, decreased 
differentiation and increased mitotic activity [15]. The conformations and quantities of 
nucleic acids, proteins, lipids and carbohydrates are also altered when a normal cell 
becomes neoplastic. These morphological and biochemical changes vary between the 
type and location of the cancer [16].  
 
Benign tumours are rarely fatal, but can cause health problems depending on 
their anatomical location. Malignant tumours, on the other hand, progress and usually 
result in mortalities if the tumour goes unnoticed or treatment is not successful. 
Malignant tumours are typically differentiated from benign tumours by 
histopathological observation of invasion and identification of tumour metastasis within 
the tissue [17].     
 
A metastasis occurs when cancer cells detach themselves from the malignant 
tumour and travel to other sites where they form deposits [18]. Within 24 hours of 
tumour cells entering the blood stream only about 0.1% is still viable, and of those, only 
0.01% will go on to produce metastases; consequently, only a minority of primary 
malignancies result in the formation of metastases at other locations [19]. The process 
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of metastasis from the primary cancer to a secondary organ is displayed in Figure 2. 
Tumour cells are genetically less stable than normal cells [20] and are highly 
heterogeneous. Cells with a high metastatic potential have been reported to have a 
higher rate of mutation than those with a low metastatic potential and thus may 
genetically differ from their primary cells [19]. Conversely, comparative genomic 
hybridisation has produced data showing a high level of conformity between brain 
metastases and their corresponding primary cancers at a chromosomal level [21].    
 
Figure 2: Schematic diagram showing the process of metastasis. Replicated from [19]. 
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1.2 The diagnostic modalities of metastatic brain cancer 
 
1.2.1 Associated symptoms of brain cancer 
 
The symptoms associated with brain tumours can be produced as a result of an 
increase in intracranial pressure caused by the tumour mass and have a significant 
impact on a patient’s quality of life. Approximately, 66% of people with brain 
metastases exhibit neurological symptoms at the time of diagnosis, including: 
headaches, seizures, altered vision, neurocognitive dysfunction and strokes, however, 
the other 33% do not [8]. The prognosis of patients is poor and individuals are expected 
to live only a few months after diagnosis of the brain metastasis [22]. The accurate and 
rapid diagnosis of disease allows early intervention of the correct treatment. This leads 
to an increase in life expectancy and quality of life for the patient, which in turn relieves 
economic resources within healthcare [23]. Currently, diagnosis of a brain tumour is 
carried out by a series of various components, comprising of: medical history, physical, 
neurological and laboratory examinations [24].       
 
1.2.2 Preoperative diagnosis 
 
At present, neurological examinations consist of brain scans, such as magnetic 
resonance imaging (MRI), computed tomography (CT) and positron emission 
tomography (PET), to initially detect and assess the suspected brain tumour [25]. These 
imaging techniques allow non-invasive, in vivo monitoring of the brain enabling 
analysis of the existent mass, its tumour margins and its location [24]. These 
examinations are only used as a preliminary assessment due to the risk of misdiagnosis 
when using the aforementioned methods alone for identification of tumours. False 
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positive (FP) diagnoses of either metastatic or primary cancers occur in 11% of patients 
with brain lesions when based only on the MRI scan. Further examinations must be 
conducted to allow a more accurate diagnosis [26].   
 
1.2.3 Biomarkers 
 
 Biomarkers are used in population screening studies, disease diagnosis, 
prognosis and monitoring. Biomarkers have been identified through techniques such as 
immunological assays [27]; Table 1 shows a selection of the biomarkers that are 
currently used for cancer detection. Biomarkers have the potential to be very beneficial 
for population screening and early disease detection. However, they are not universally 
accepted as their specificities and sensitivities are not high enough and false positives 
occur too frequently. It is thought that the most single powerful biomolecules have 
already been identified and thus sensitivities and specificities can only improve by the 
identification and analysis of multiple biomarkers to enable cancer diagnosis [27]. 
  
Table 1: Established biomarkers and the corresponding cancer they relate to. (Adapted from [27]). 
Biomarker Cancer 
α-Fetoprotein (AFP) Hepatoma; testicular cancer 
Carcinoembryonic antigen (CEA) Colon; breast; lung; pancreatic 
PSA Prostate cancer 
CA125 Ovarian cancer 
CA15.3 Breast cancer 
CA19.9 Gastrointestinal 
Immunoglobulins B cell discrasias 
Chroriogonadotropin (hCG) Testicular cancer 
Steroid hormone receptors Breast cancer 
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1.2.4 Histopathological diagnosis 
 
The current method of choice for diagnosing metastatic brain tumours and their 
primary sites is histopathological analysis of stained tissue sections. Staining is carried 
out in order to visualise cellular components. Haematoxylin and Eosin (H&E) staining 
is the most common and well established method for staining tissue sections for 
examination of cancers. Haematoxylin dyes the nuclear component of cells blue and 
eosin dyes the cytoplasm and connective tissue pink [28]. Neoplasms are identified 
histologically by increased cellular crowding and disorder in the tissue [16].  Analysis 
consists of assessment of the morphology, architecture and staining of the tissue. 
However, this method of diagnosis requires a trained neuropathologist, is invasive and 
has a lengthy processing time, delaying treatment. Histopathological examination is also 
a highly subjective method of diagnosis [29, 30] and it has been reported that 
pathological diagnostic discrepancy can occur in 1-43% of specimen [31, 32]. False 
negatives (FN) may occur as a result of the biopsy procedure failing to locate and 
remove the abnormal lesion leading to only normal tissue being analysed. Treatments 
are then chosen based only on the histopathological diagnosis which could potentially 
be life threatening [33]. 
 
Adenocarcinoma is the most frequent type of primary cancer for brain 
metastases of unknown primary (BMUP). Tumours can be poorly differentiated in 
adenocarcinomas and the resulting brain metastases. The microscopic appearance of 
adenocarcinoma metastases from different primary locations is similar, and 
consequently impairs histopathological examination and hence diagnosis. The 
development of diagnostic techniques that can accurately identify the primary cancer 
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origin from analysis of the metastatic brain tissue alone is needed to allow early 
intervention and correct treatment in order to increase patient survival time [34].                 
    
 
1.3 Raman Spectroscopy 
 
1.3.1 Fundamentals of Raman spectroscopy 
 
Raman spectroscopy is based on the interaction of electromagnetic radiation, in 
the form of monochromatic light, with matter. Light is scattered either elastically or 
inelastically as it hits the sample. The majority of light is elastically scattered, known as 
Rayleigh scattering, and does not involve an exchange in energy between the incident 
light and the molecules within a sample. Rayleigh lines are thus scattered at the same 
frequency as that of the incident light. Inelastically scattered light, known as Raman 
scattering, involves an energy exchange between the incident light and the molecules 
within a sample in accordance with quantal laws [35]. Raman scatter is less intense than 
Rayleigh scatter and generally comprises no more than 0.001% of the total scattered 
light [36]. The energy change (ΔE) must be equal to the difference in energy between 
two allowed states of the molecule, thus, representing a change in the molecules 
rotational or vibrational energy. When a molecule gains energy photons will be 
scattered with hѵ-ΔE and the light will have a frequency of ѵ-ΔE/h. Conversely, if a 
molecule loses energy, photons will be scattered with hѵ+ΔE and the light will be 
scattered with a frequency of ѵ+ΔE/h. Where hѵ is the photon energy, ѵ is the radiation 
frequency and h is Planck’s constant [35]. Scattered light (SL) with a lower frequency 
to that of the incident light is called Stokes scattering (SS). This is where energy is 
transferred from the incident light to the molecule; the excited molecule does not return 
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to its ground state from the virtual state, but to its vibrational state, and a lower energy 
photon is emitted. Scattered light of a higher frequency to that of the incident light is 
called Anti-Stokes scattering (ASS). This is where the molecule is already at its 
vibrational state, due to prior excitement or thermal disturbance, and the molecule is 
excited to a virtual state. Energy is transferred to the incident light from the molecule, 
returning it to its ground state, and a photon of higher energy is emitted [37, 38]. Figure 
3 displays a basic diagram of energy levels for Rayleigh and Raman: Stokes and Anti-
Stokes scatter. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Energy level diagram for Rayleigh and Raman scattering. (Adapted from [39]). 
 
 
If a molecule is exposed to a static electric field it becomes distorted as the 
positively charged nuclei are attracted toward the negative pole and the negatively 
charged electrons are attracted toward the positive pole. The charge centre separates and 
an induced dipole moment occurs as a result, the molecule is polarised. A change in the 
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polarisability, reflected in the magnitude or direction of the polarisability ellipsoid, must 
be caused by molecular rotations and vibrations for its modes to be Raman active. The 
number of normal vibrational modes a molecule has can be calculated by the degrees of 
freedom: either 3N-5 for linear molecules, such as CO2, or 3N-6 for non-linear 
molecules, such as H2O; where N represents the number of atoms in the molecule. The 
vibrational modes of a molecule can include symmetric stretching, asymmetric 
stretching and bending, but not all vibrational modes will be Raman active (Figure 4) 
[35].   
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Figure 4: Diatomic and polyatomic modes of vibration (adapted from [35]). 
 
 
1.3.2 Application of Raman spectroscopy in cancer diagnostics 
 
Raman spectroscopy measures the energy shift and intensities of scattered 
photons [40]. It is both a quantitative and qualitative technique which is able to provide 
molecular information about samples from their spectra, regarding conformation and 
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composition [41, 42]. The frequencies and intensities of Raman bands are based on the 
atoms involved, the conformations and the chemical environments of the bonds, and 
their concentrations within a molecule; and are thus unique to specific molecules, 
enabling the production of characteristic spectra and the identification of molecules 
within a sample [43].  
 
Raman spectroscopy is a non-destructive technique which is able to analyse 
samples in any state, without extensive solvent use or sample preparation. It is a rapid 
and economical method of analysis. Moreover, it is a relatively low-risk and easy 
technique to use [44]. Measurement of a single cell can be achieved with Raman 
spectroscopy due to its good spatial resolution [45]. It is a non-ionising technique and 
water presence does not significantly alter spectra produced, as it is a weak light 
scatterer. With the use of fibre optic probes, Raman spectroscopy can be used for in vivo 
measurements, giving it an advantage over other vibrational techniques, such as infrared 
spectroscopy, which is highly affected by H2O absorption bands in spectra  [46] [47]. 
With the use of deep Raman spectroscopic techniques, measurements can be made up to 
several millimetres into tissue samples [48]. 
 
Tumours that are not completely resected during surgery to remove all 
neoplastic and pre-neoplastic cells have a greater chance of reoccurrence [49]. Within 
five years after simple surgical excision of the tumour, cancer recurrence is reported to 
occur in 10.1% of basal cell carcinoma cases [50].  There cannot be an application of 
safety margins for the excision of brain tumours, as there is in extracerebral cancers, due 
to the brain’s high level of functional responsibility. Thus, accurate identification of 
tumour margins is essential for an optimistic prognosis [51].   The advantage of in vivo 
analysis that Raman spectroscopy offers allows real-time analysis of tissue. This can aid 
25 
 
tumour margin identification during surgery, help direct biopsies to enable complete 
removal of cancerous tissue [52], whilst preserving the surrounding healthy tissue [53].  
 
When analysing biological tissue at short wavelengths, below 500 nm, Raman 
spectroscopy can suffer from intense spectral backgrounds, thought to be as a result of 
fluorescence, which can significantly affect the quality of the spectra. The use of near 
infrared (NIR) lasers, such as 785 nm, to irradiate the sample reduces this phenomenon; 
as wavelengths in this region do not typically induce the electronic transitions in tissue 
chromophores that contribute to fluorescence. Dispersive Raman spectrometers enable 
the use of 785 nm lasers and help to reduce the spectral background that can result when 
analysing biological materials. Charged coupled device detectors are employed in 
dispersive instruments and have assisted the development of portable Raman 
spectrometers [54].  
 
Immersion Raman spectroscopy utilises an immersion lens which is in direct 
contact with an appropriate liquid, such as deionised water, which covers the sample 
under analysis. Bonnier et al. [55] describe and demonstrate the successful use of 
immersion Raman spectroscopy for both live cell and in vitro tissue specimens on CaF2 
substrate, and observe the improvement of spectral quality, sample stability and the 
reduction of spectral background [55, 56]. They determined that fluorescence, 
contributing to spectral background, is only significant at short wavelength laser 
sources, as proteins typically only fluoresce with wavelengths below 500 nm. Hence, 
the background of spectra acquired using 785 nm lasers should not be attributed to 
fluorescence but to sample morphology, associated with scattering of the incident light 
and Raman lines that cause non-collimated entry into the spectrometer. The exchange of 
a tissue/air interface with a tissue/liquid interface results in more uniform refractive 
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indices thus, reducing this level of stray light, and in turn, the intensity of the spectral 
background. Submerging the sample in liquid also protects tissue specimens from 
photo-damage. In turn this enabling more powerful lasers of shorter wavelengths to be 
used and longer acquisition times and a higher number of accumulations to be 
employed, hence, improving spectral quality [55-57]. 
 
The potential of Raman spectroscopy as a diagnostic tool for diseases has been 
demonstrated by a variety of studies [33, 58-69]. Many papers have shown the ability of 
Raman spectroscopy to diagnose cancers, including: brain cancers  using tissue on low-
E microscope slides and CaF2 slides [58, 59], lung tumours through the analysis of 
bronchial tissue sections [60],  gastric adenocarcinomas using tissue samples [61, 62], 
non-melanoma skin cancers from the analysis of tissue in vivo [63], laryngeal cancers 
from tissue at endoscopy [64], breast cancers using both fresh and frozen tissue 
specimens [65, 66], cervical cancers from tissue in vivo [67], bladder and prostate 
cancers from tissue sections [68, 69] and oesophagus and colon cancers through the 
analysis of snap frozen tissue on CaF2 [33]. 
     
1.3.3 Raman spectra of cancerous tissue 
 
 Significant biochemical differences should be present between neoplastic and 
healthy tissue that arise as a result of an alteration in biological processes [70]. When a 
tissue becomes diseased, molecular composition is altered, DNA concentrations in the 
cell increase and the amounts of other components in the cell vary compared with non-
diseased cells [71]. These molecular changes should be expressed in its vibrational 
spectra, enabling the spectral discrimination between diseased and healthy tissue. As a 
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result, significant spectral differences can act as markers for the identification of 
specific diseases [52].  
 
Gajjar et al. [58] observed significant (P ≤ 0.0001) differences between the 
Raman spectra of brain tumour tissue and healthy brain tissue at the following spectral 
points: 1483 cm
-1
 (CH2 bend), 852 cm
-1
 (tyrosine and proline), ≈ 1235 cm-1 and 1276 
cm
-1
 (Amide III), 1654 cm
-1
 (Amide I) and 997 cm
-1
 (phospholipids and glucose-I-
phosphate). They also reported the ability of Raman spectroscopy to successfully 
discriminate between different brain tumour types. They observed that metastatic brain 
tissue could be differentiated from healthy brain tissue at the following spectral points: 
997 cm
-1
 (phospholipids and glucose-I-phosphate), 1077 cm
-1
 and 1446 cm
-1
 (lipids and 
proteins), 1241 cm
-1
 (Amide III), ≈ 1460 cm-1 (cytosine) and 1654 cm-1 (Amide I) [58]. 
 
 The Raman spectra of biological samples can be largely affected by artefacts. 
Gaussian noise, as a result of fluorescence of the sample or thermal fluctuations on the 
charged coupled device (CCD), can result in unwanted intense backgrounds. The result 
of this effect needs to be reduced prior to data analysis through background correction 
pre-processing methods. Cosmic spikes can also occur in the spectrum, caused by high 
energy particles hitting the CCD, but this effect can be eliminated during measurements 
by accumulating the spectra more than once [72]. 
 
1.3.4 Raman Spectroscopy Substrates 
 
Substrates are needed in Raman spectroscopy to support the samples during 
analysis. Samples are often relatively thin allowing incident light the opportunity of 
interacting with the substrate below. This interaction has an effect  on the spectral 
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background; thus, the correct choice of substrate for Raman analysis is essential for 
reducing this background and optimising the quality of the spectral data [57].   
 
Common spectroscopy substrates used currently include quartz, calcium fluoride 
(CaF2) and low-emissivity (low-E) microscope slides. Spectrosil, a type of quartz 
substrate, is approximately 0.5 mm thick, has a perimeter of 7.5 cm x 2.5 cm and costs 
typically £9.00 per slide. CaF2 is approximately 1 mm thick, has a perimeter of 2.5 cm x 
2.5 cm and costs £35 per slide. MirrIR, a low-E slide, is approximately 2 mm thick, has 
a perimeter of 7.5 cm x 2.5 cm and costs £1.50 per slide. Low-E substrates are glass 
slides that are coated with a metallic reflective coating, such as tin oxide/silver, 
allowing high transmission of visible light [73].  
 
Draux et al. [74] investigated the use of different optical substrates for Raman 
measurements of live cells. The substrates they analysed were CaF2, quartz and zinc 
selenide (ZnSe). They reported that ZnSe is toxic to living cells and hence were unable 
to take measurement of the live cells using this substrate. They found that both the CaF2 
and quartz produced Raman spectra with comparable signal-to-noise ratios and that 
neither substrate interfered with the obtained results. Although, they concluded that due 
to quartz having no effect on cell growth and morphology, it is the best substrate to use 
for Raman spectroscopic measurement of live cells [74]. 
  
1.4 Dewaxing of Paraffin embedded tissue samples 
 
Raman spectroscopy can analyse tissue samples in a variety of different 
conditions. These most commonly consist of tissues that have been formalin fixed 
paraffin preserved (FFPP), frozen, and fresh tissue. Using tissue in an unaltered state is 
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desirable for Raman analysis, but fresh tissue is not easily accessible and is difficult to 
section [75]. Frozen and FFPP tissues are frequently used as alternatives to fresh tissue 
due to better accessibility. FFPP tissue is often chosen over frozen tissue due to its long 
preservation time, easy obtainability and storage and the ability to use it for carrying out 
retrospective studies [76].  
 
In order to prevent degradation, by halting biochemical processes, biological 
tissues must be fixed. The most frequently used fixative solution is formalin which uses 
bonding reactions to work on tissue proteins [77]. Huang et al. [78] investigated the 
impact of fixation on tissues; they observe formalin fixation artefacts at 980 cm
-1
 – 1100 
cm
-1
 and 1480 cm
-1 – 1650 cm-1; yet, they report that the major Raman peaks for 
proteins and lipids are not altered by formalin fixation. However, they conclude that 
with a large focus being on in vivo applications, fresh tissue is always preferable for 
analysis in order to generate results that would be more similar to those experienced in 
clinical settings [78]. 
 
Tissue is often impregnated with a medium for preservation and to add support 
to aid sectioning through microtomy. The most common and efficient medium for 
embedding tissue sections is paraffin wax. The sections are dehydrated, washed in an 
organic solvent, saturated with molten paraffin wax and are then left to cool to enable 
the wax to solidify. FFPP tissue has to be dewaxed prior to spectroscopic analysis to 
reduce the spectral contribution of the paraffin wax and allow the tissue to be as similar 
to an in vivo state as possible for analysis [79]. Ó Faoláin et al. [79] observed that 
paraffin wax contributes to Raman spectra at wavenumbers; 1063 cm
-1
, 1133 cm
-1
, 1296 
cm
-1
 and 1441 cm
-1
 corresponding to C-C, CH2 and CH3 bonds as a result of its straight 
hydrocarbon chain structure. They also reported a less intense peak at 1004 cm
-1
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n=Paraffin 
Iso=Paraffin
 
Cycloparaffin 
corresponding to the C-C bonds of an aromatic ring, due to a small number of 
cycloparaffins [79]. The structure of paraffin is displayed in Figure 5. Xylene is 
frequently the method of choice for dewaxing FFPP tissue sections due to its efficacy 
and rapidity in doing so. However, associated problems such as its high toxicity and 
flammability can lead to the use of histoclear as it is a suitable alternative. Histoclear is 
not toxic or flammable and is biodegradable [79]. Ó Faoláin et al. [79] evaluated the 
efficacy of these two common dewaxing solvents and also looked into the potential use 
of hexane for dewaxing tissue. They observed that hexane is better at dewaxing FFPP 
tissue than both xylene and histoclear; however, requires 18 hours of tissue submersion 
in the solvent and is currently not an accepted solvent for dewaxing tissue sections [79].  
 
 
 
Figure 5: Molecular structure of paraffin (Replicated from [79]). 
 
Chemical dewaxing is not 100% efficient and can also alter samples. Digital dewaxing 
methods have been developed, utilising the application of independent component 
analysis, to identify and subtract paraffin peaks in the spectra [80].  
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1.5 Scanning Electron Microscope/Energy dispersive analysis of X-rays 
 
Scanning electron microscopy (SEM) combined with energy dispersive analysis 
of X-rays (EDAX) is used to observe and analyse specimens microscopically, and 
tentatively identify and quantify the elements present in samples. SEM is based on the 
detection of secondary electrons and it takes place under vacuum to enable an optimum 
mean free path, so the electrons are not scattered. An electron gun emits high energy 
electrons which are focused into a small-diameter electron probe by magnetic lenses and 
serially scanned across the specimen surface by scanning coils. When the primary 
electron beam hits the surface of the specimen, secondary electrons are knocked loose 
from its surface. These electrons are detected and then amplified to produce an image of 
the specimen, created using the count of secondary electrons at each scanned point 
along the surface. Instrumental resolution is typically between 1 nm -10 nm [81, 82].  
  
Samples are often placed on aluminium stubs for analysis and held there using 
carbon tape which enables good electrical contact between the sample and the 
aluminium stub. Samples are illuminated with a high energy beam of electrons; thus, 
SEM analysis requires samples to be good electrical conductors. A sputter coater is used 
prior to SEM analysis which coats samples with gold to ensure they conduct electricity 
[83].   
 
EDAX uses X-rays, which are generated as a result of the interaction between a 
high-energy electron beam and a solid, to produce a chemical spectrum of the analysed 
material. Essentially, all elements with atomic numbers 4 to 92 can be detected. It is 
both a qualitative and quantitative technique for the analysis of elemental components 
within materials. For qualitative analysis, detection of the specific x-ray wavelengths is 
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required. Quantitative analysis requires measurement of the intensities of the 
wavelengths for each element, which are compared with the intensities produced from 
known calibration standards [84].   
  
1.6 Study aims and rationale 
 
1.6.1 Working hypothesis and rationale   
 
 The working hypothesis of this study is that Raman spectroscopy will be able to 
discriminate metastatic brain tumours from normal brain and GBM tissue based on 
Raman spectra.  
Current detection methods for metastatic brain cancer have a long diagnostic 
window, require highly trained personnel and are subjective. Raman spectroscopy can 
provide non-subjective, minimally invasive, non-destructive, rapid and economical 
diagnosis and would thus be an ideal method for diagnosing metastatic brain cancer 
[85].  
 
1.6.2 Main aim of study 
 
The primary aim of this study was to assess the diagnostic potential of Raman 
and immersion Raman spectroscopy for metastatic brain cancer. This was done by 
analysing metastatic, normal and GBM brain tissue, to identify if any spectral 
differences can be observed.  
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1.6.3 Secondary aims of study 
 
A further aim of this study was to investigate the ability of Raman spectroscopy 
to identify the primary cancer site of origin of brain metastases. This was conducted by 
analysing metastatic brain tissue from various primary cancers of: lung, breast, 
oesophagus and stomach, colon/rectum and melanoma, and identifying if any spectral 
differences are present that can demarcate the groups and thus enable identification of 
the primary cancer.  
 
The study also involved an investigation into the effect of spectroscopic 
substrates on tissue preparation methods and the outcome of spectra. This was carried 
out by comparing the background and tissue spectra produced from Raman 
spectroscopy of three common substrates: CaF2, Spectrosil quartz and Low-E, to 
analyse the quality of both the spectra and the dewaxing procedure.  
 
A comparison between Raman and immersion Raman spectroscopy, using a 785 
nm laser, was carried out to ascertain which method yields better quality spectra for 
spectral histopathology. This involved an examination of the tissue spectra produced by 
both methods.  
 
Raman spectroscopy can be carried out using a variety of wavelengths for the 
incident laser. This study evaluated the differences in the resulting spectra of tissue 
samples produced from Raman spectroscopy using a 532 nm laser line and a 785 nm 
laser line. This was carried out in order to assess which wavelength laser produces the 
better quality spectra for the specimens in this study.              
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Chapter 2  
Materials and Methods 
 
2.1 Summary of materials used in the study 
 
Table 2 displays a summary of all the materials employed to carry out this study.  
 
Table 2: Summary of tissues, reagents, instrumentation and materials used in the study 
Tissue Reagents Instrumentation Materials 
Normal brain Ethanol Raman spectrometer Spectrosil substrate 
Metastatic brain Haematoxylin microtome CaF2 substrate 
Colon/rectum Eosin Desiccator Low-E substrate 
Oesophagus/stomach Deionised water  SEM-EDAX  
Breast  Atomic force microscope  
Skin  Optical microscope  
 
2.2 Study participants 
 
Tissue samples were obtained from formalin fixed paraffin preserved (FFPP) 
tissue blocks from the Brain Tumour North West (BTNW) bio-bank under ethical 
approval (BTNW/WRTB 13_01). Patient data consisted of histological information, 
patient gender and date of birth, origin of metastasis/histological subtype. A total of 48 
tissue specimens were obtained from 41 different patients. Tissue consisted of normal 
brain samples (n=7), glioblastoma multiforme (GBM) brain samples WHO (world 
health organisation) grade IV (n=5), metastatic brain samples (n=29) and primary 
cancer tissue samples (n=7). The normal tissue all had a normal microscopic appearance 
with no detectable tumour present, coming from patients with meningiomas, aneurisms, 
chondrosarcomas, oedematous changes or no disease. Table 3 displays further 
information about the tissue specimens. Sections were cut, by microtomy, at both 4 µm 
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onto glass microscope slides and 10 µm onto spectroscopic substrates: low-E MirrIR 
slides (Kevley Technologies, Chesterland, OH, 44026, USA), Spectrosil quartz (Starna 
Scientific) and calcium fluoride (CaF2) (Crystran). 
 
Table 3: Patient details with histological subtype and metastatic origin.    
BTNW no. Gender DOB Origin of metastasis/histological 
subtype 
119 F 26/06/1963 Breast (met and primary site) 
707 F 07/08/1945 Breast (met and primary site) 
756 F 15/03/1957 Breast (met and primary site) 
888 M 25/11/1948 Colon/rectum (met and primary site) 
985 M 05/02/1933 Melanoma (met and primary site) 
988 M 30/12/1949 Oesophagus & stomach (met and 
primary site) 
1001 F 20/12/1944 Lung (met only) 
690  F 25/10/1960 Breast (met and primary site) 
1004 F 03/09/1956 Breast (met only) 
998  M 25/07/1946 Colon (met only) 
1020 F 05/06/1948 Breast (met only) 
2 F 28/10/1937 GBM 
3 F 22/09/1981 GBM 
4 M 08/12/1942 GBM 
5 F 29/10/1958 GBM 
7 M 14/04/1939 Normal Brain  
10 F 13/06/1929 GBM 
78 F 24/09/1955 Lung (met only) 
106 F 14/02/1965 Normal Brain 
132 F 24/06/1943 Normal Brain 
136 F 25/09/1956 Normal Brain 
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137 M 26/04/1944 Colon/rectum (met only) 
164 M 10/04/1954 Oesophagus & stomach (met only) 
184 F 21/11/1948 Lung (met only) 
215 M 21/01/1973 Lung (met only) 
274 M 12/07/1940 Colon/rectum (met only) 
295 F 12/06/1936 Lung (met only) 
358 M 08/05/1935 Melanoma (met only) 
409 F 08/08/1925 Colon/rectum (met only) 
444 M 30/01/1978 Normal Brain 
509 M 11/02/1930 Melanoma (met only) 
517 F 05/06/1955 Lung (met only) 
521 M 18/01/1949 Oesophagus & stomach (met only) 
562 F 12/03/1953 Lung (met only) 
567 F 09/04/1947 Melanoma (met only) 
668 F 30/08/1943 Colon/rectum (met only) 
678 F 13/11/1961 Normal Brain 
688 F 15/06/1965 Melanoma (met only)  
694 M 18/09/1951 Lung (met only) 
721 F 04/01/1976 Oesophagus & stomach (met only) 
772 M 21/09/1972 Normal Brain 
  
 
2.3 Tissue preparation for histological examination  
 
Tissue sections on the microscope slides needed to undergo staining with 
Haematoxylin and Eosin (H&E) for parallel histological examination; to allow 
microscopic examination the sections cannot be too thick and 4 µm is standard. Using 
standard procedures, the sections were de-waxed before staining by: 2 x 5 minute baths 
of histoclear followed by 2 x 5 minute baths of ethanol. The tissue sections were 
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washed in distilled water for 5 minutes after de-waxing, prior to H&E staining. Sections 
were bathed in haematoxylin for 5 minutes and then washed in warm tap water to allow 
the nuclei to turn blue. The sections were then covered in eosin for 4 minutes and rinsed 
with distilled water. Finally, the tissue sections were dehydrated in 2 x 5 minute baths of 
ethanol and cleared in 2 x 5 minute baths of histoclear, and then protected and preserved 
through the application of histomount and a coverslip. The sections were then 
microscopically examined in order to identify the metastatic sites present in the tissue.   
 
 
2.4 Tissue section preparation for Raman spectroscopic analysis 
 
The tissue sections on Raman substrates must be thick enough for spectral 
analysis, to avoid large amounts of substrate contribution to the spectra, and needed to 
be de-waxed prior to Raman analysis in order to reduce paraffin peaks in the spectra. 
The de-waxing procedure, consistent with standard procedures [58], was carried out by 
an initial 3 x 5 minute baths of histoclear followed by 3 x 5 minute baths of ethanol. The 
sections were left to air dry for 30 minutes, placed in a Petri dish and stored in a 
desiccator until spectroscopic analysis.  
  
2.5 Raman spectroscopy instrumentation and analysis 
 
Spectroscopic measurements were carried out using a Horiba Jobin-Yvon 
LabRAM HR800 spectrometer (Figure 6). An air cooled CLDS point mode diode 785 
nm laser with a single edge filter (cut off to 100 cm
-1
)
 
and an output power of 300 mW 
was used to acquire spectra. A narrow bandwidth, solid state diode 532 nm laser with 
single edge filter (120 cm
-1
) and an output power of 50 mW was also used for spectral 
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acquisition. The aforementioned lasers were used with gratings of 300 gr/mm and 600 
gr/mm respectively and blazed at 1000 nm for the near-infrared region and 500 nm 
respectively. Non-immersion point spectra were acquired using a 0.9 (x 100) (MPlanN) 
objective, with a 1 µm spot size, non-immersion spectral maps were collected using a 
0.75 (x 50) (MPlanN, Olympus) objective and immersion point spectra and maps were 
taken using a 1 (x 60) objective (LUMPlanFLN, Olympus), with a 1.5 µm spot size. The 
confocal hole was set at 100 µm for the 785 nm spectral collections and 200 µm for the 
532 nm spectral collections. The detectors used were an Andor electromagnetic (EM) 
CCD and a Synapse CCD, with 1024 x 256 pixels and cooled at –70 oC, for the laser 
line 785 nm and 532 nm respectively. The spectra were measured across the wavelength 
range of 400 cm
-1–1800 cm-1.    
 
 
Figure 6: Horiba Jobin-Yvon LabRAM HR800 Raman spectrometer. 
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The instrumentation was calibrated before operation to silicon at the spectral line 
at 520.8 cm
-1
. Spectra collected using a 100% exposure 785 nm laser were acquired for 
30 seconds and accumulated twice, with both the immersion and non-immersion 
objectives. Spectra collected using the 532 nm laser were 100% exposed with an 
acquisition time of 4 seconds and accumulated twice. Three to five areas were used to 
produce at least 20 spectra per tissue sample, targeting the nucleus of cells. A total of 
3054 spectra were generated through the production of at least 20 spectra from three to 
five areas on each tissue samples, depending on size, to enable the production of results 
that are good representations of each sample. Immersion Raman spectroscopy consisted 
of tissue submersion in deionised water which was then placed in direct contact with the 
immersion objective lens. 
 
Spectroscopic measurements of the paraffin wax were carried out on a Horiba 
Jobin-Yvon LabRAM HR800 confocal Raman Spectrometer (Figure 7). The detector 
used with this system was an air-cooled open electrode 1024 x 256 pixel CCD detector. 
A x 50/0.55 long working distance microscope objective (PL FLUOTAR, Leica) was 
employed for the measurements. Spectral acquisition was carried out for 30 seconds and 
accumulated twice using a 785 nm laser as the incident source with a filter set to 100%. 
The 785 nm laser line has an output power of 400 mW and has a power at the sample of 
100 mW.     
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Figure 7: The Horiba Jobin-Yvon LabRAM HR800 confocal Raman Spectrometer used to take paraffin 
wax measurements. 
 
 
2.6 Data pre-processing and multivariate analysis  
 
Pre-processing and multivariate analysis were carried out on the raw data using 
LabSpec 6 spectroscopy software suite (HORIBA Scientific) and MATLAB version 
7.11.0 (R2010b) (The MathWorks, Inc., USA) using in-house written software.  
 
Pre-processing of the data was kept minimal to allow a better level of 
reproducibility. Initially, all the data were subjected to a visual quality test to ensure 
only adequate spectra were included in the analysis. Vector normalisation was applied 
to all the raw data in MATLAB using codes written by Dr A. Henderson. Biological 
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samples are heterogeneous and the environmental and instrumental settings are 
changeable, thus, normalisation is applied to mathematically account for this 
inconsistency through the identification of non-disease attributed variability between the 
data prior to adjustment [86]. A fifth order polynomial fit was applied and then 
subtracted to each of the spectra followed by 7 point smoothing in the LabSpec 6 
software. A polynomial fit is a method of baseline correction whereby non-constant, 
low frequency baselines are adjusted for. Smoothing is a method of local averaging that 
is applied to the data to produce de-noised spectra [86]. Paraffin peaks were manually 
removed from the spectra for multivariate analysis at the following wavenumbers: 882 
cm
-1
 - 912 cm
-1
, 1051 cm
-1
 - 1071 cm
-1
,  1115 cm
-1
 - 1143 cm
-1
, 1163 cm
-1
 – 1187 cm-1, 
1284 cm
-1
 – 1305 cm-1 and 1407 cm-1 – 1501 cm-1.    
 
Multivariate analysis was then carried out on the spectral set, employing 
principal component-discriminant function analysis (PC-DFA). Principle component 
analysis (PCA) is an unsupervised method of identifying patterns in data, and 
expressing the data in such a way to highlight similarities and differences. PCA can be 
used to reduce the dimensionality of the dataset prior to DFA. Spectra for PC-DFA were 
organised into two sets: a training set and a blind test set. DFA is a supervised 
technique, based on the PCs and the DFA algorithm’s prior informed knowledge of 
group memberships. It maximises the intergroup variance and minimises the intragroup 
variance. Hence, discrimination between groups is achieved. The PC-DFA model was 
tested by a blind test set using one third of the total dataset which was randomly 
selected, supplied to the model and then analysed on a graphical output by identifying 
what group they were classified as belonging to [87].  
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Error ellipses were used to highlight 90%, 95% and 99% confidence limits on 
the PC-DFA graphical output, using error_ellipse.m written by A.J. Johnson and 
obtained from Matlab central file exchange. These were formed by calculated the 
covariance matrices from the discriminant function score matrix. The mean of each data 
group defined the centroid of the ellipsoid.  
 
The classification sensitivities and specificities were calculated from the DFA 
score plot based on the error ellipses. This study investigated three different PC-DFA 
models. Sensitivity is the percentage of a population with a disease that are classified as 
positive and specificity is the percentage of a population without a disease that are 
classified as negative [88] .  
 
Sensitivity = [TP/TP+FN] x 100  
Specificity = [TN/TN+FP} x100 
 
Where: 
TP = true positive 
- Number of spectra correctly classified as cancerous 
FN = false negative 
- Number of spectra incorrectly classified as not-cancerous 
TN = true negative 
- Number of spectra correctly classified as not cancerous 
FP = false positive 
- Number of spectra incorrectly classified as cancerous 
[89] 
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2.7 SEM-EDAX 
 
The FEI Company Quanta series 200 SEM/EDAX, with an xT microscope 
system, was used to generate microscopic images and produce information on elemental 
composition of the three substrates. The substrates were coated in gold prior to 
SEM/EDAX analysis and situated on a carbon tape for analysis. 
 
2.8 Atomic force microscope (AFM) 
 
 The atomic force microscope (AFM) model used to image the samples for 
surface morphology for this study is the MFP-3D-BIO (Asylum Research), with 
Olympus silicon AC160 cantilevers. The tips were 160 nm long with resonant 
frequencies typical of 320 kHz. A/C mode was employed for operation to reduce 
tip/sample interaction. 
 
2.9 Statistical Analysis 
All data were analysed using relevant statistical test. All data were analysed 
using in-house written software on Matlab. The data was interrogated using PCA and 
PC-DFA methods. All experiments were performed more than three times to ensure 
reproducibility of the results.  
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Chapter 3 
Results and Discussion 
 
3.1 Microscopic examinations of H&E stained sections  
 
Figure 8 shows the microscopic images of the H & E stained tissue specimens at 
x 100 magnification of normal brain, GBM, Oesophagus and stomach metastasis, breast 
metastasis, colon/rectum metastasis, lung metastasis and melanoma metastasis. It can be 
observed that normal brain, metastatic brain and GBM brain tissue architecturally differ 
from one another and between the metastatic types. 
Figure 8: Microscopic images of H&E stained tissue samples of normal brain, metastatic brain (from 
oesophagus and stomach, breast, colon/rectum, lung and melanoma as labelled above) and GBM brain 
WHO grade IV (x 100). 
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3.2 Substrate Study 
 
Raman spectra were acquired of the three substrates: low-E, Spectrosil and CaF2 
using the 785 nm laser under the same conditions, which display the spectral 
‘fingerprints’ of the substrates, shown in Figure 9. This is to ascertain the impact of the 
substrates’ contribution to the spectral background and hence establish their level of 
interaction with the incident light source and the impact they have on the spectra of 
tissue samples.  
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Figure 9: Original spectral plot showing raw spectra of the substrate backgrounds: low-E (top), Spectrosil (middle) and CaF2 (bottom). 
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It can be observed that low-E has the highest intensity baseline and CaF2 has the 
lowest intensity baseline of the three substrates. The baseline of Spectrosil is slightly 
higher than that of CaF2 and has apparent peak contributions at approximately 600 cm
-1
 
and 800 cm
-1
. These results indicate that the spectra taken from samples on CaF2 are 
less affected by substrate background and should display spectral information relating 
only to the sample of interest and low-intensity peaks more clearly than either low-E or 
Spectrosil substrates. 
 
Each substrate was analysed using the scanning electron microscope and energy 
dispersive analysis of X-rays (SEM/EDAX) instrument, in order to assess the chemical 
constituents present and microscopically observe the substrate surface. Figures 10-12 
show the results of the analysis and the associated microscopic images of these 
substrates. The Spectrosil substrate exhibits peaks of silicon and oxygen. CaF2 exhibits 
peaks of calcium, fluoride and oxygen. Low-E substrates exhibit peaks of silicon, 
oxygen, cobalt, nickel, magnesium sodium, palladium, silver, cadmium, tin and 
calcium. The gold peak and carbon peak are not contributed by the specimen, but are 
present as a result of the gold used to coat the samples and the carbon tape used to 
situate the sample on.      
 
The higher number of constituents present in the low-E substrate provides more 
molecules that can interact with the incident laser of Raman spectroscopy. Thus, 
providing an explanation for the substrate’s high spectral baseline when compared with 
CaF2 and Spectrosil, which is only composed of two elements and three elements 
respectively.   
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Figure 10: SEM-EDAX of Low-E substrate acquired from three different areas. 
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Figure 11 SEM-EDAX of Spectrosil substrate acquired from three different areas. 
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Figure 12 SEM-EDAX of CaF2 substrate acquired from three different areas. 
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Spectra were acquired of the tissue samples situated on the three different 
substrates, under the same conditions using the 785 nm laser, to further ascertain the 
level of influence substrate type has on the outcome of spectra. It can be observed from 
the averaged, vector normalised spectra displayed in Figure 13 that the tissue spectra on 
Low-E has a lower signal-to-noise ratio and the peaks are visually less clear and not as 
distinguishable as those produced from tissue on either CaF2 or Spectrosil. The 
discrepancy between the spectra on different substrates shows that the substrate used 
has an effect on signal-to-noise ratio, and thus influences the resulting Raman spectra. 
 
 
 
 
 
 
 
 
 
 
52 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Original spectral plot showing the average of 458 CaF2 acquisitions (18 specimens from n=11 patients), 210 low-E acquisitions (10 speciments from n=10 patients and 
465 Spectrosil (18 specimens from n=11 patients) acquisitions from all pathologies and a raw spectrum of paraffin wax. The tissue spectra have been vector normalised and offset for 
visual clarity. The asterisks above the peaks correspond to the paraffin contributions.    
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A paraffin spectrum displays notable spectral peaks at 888 cm
-1
, 1061 cm
-1
, 
1131 cm
-1
, 1171 cm
-1
, 1294 cm
-1
, 1417 cm
-1
, 1440 cm
-1
, 1462 cm
-1
, which can be 
assigned to C-C stretching and CH2 and CH3 deformations within the molecule  [79]. It 
can be seen from Figure 13 that the spectra of tissue samples on Spectrosil and CaF2 
still exhibit paraffin peaks after the samples have been dewaxed, however, dewaxed 
tissue spectra from low-E substrates do not display any visible paraffin peaks.  
 
In order to investigate any substrate effect on the dewaxing process, the wax was 
analysed on each of the substrates without tissue present. Paraffin wax was cut at 10 µm 
sections, the same thickness as that of the tissue sections, and mounted onto the three 
different substrates. The wax was then left to melt onto the substrate for 20 minutes in 
an oven set at 60 
o
C and allowed to cool. The paraffin only samples were then dewaxed 
by the same method as the FFPP tissue samples and analysed; Figure 14 displays the 
resulting vector normalised and background subtracted spectra. Spectrosil and CaF2 
substrates continue to exhibit large paraffin peaks in their spectra, which correspond to 
the peaks displayed in the spectra of paraffin, whilst the low-E substrate exhibits no 
such peaks.  
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Figure 14: Original spectral plot showing vector normalised, background-subtracted spectra of substrates after dewaxing from: 1 CaF2 acquisition, 1 Spectrosil acquisition and 10 
averaged low-E acquisitions. The raw spectrum of paraffin wax (bottom cyan spectra) is included as a reference. The spectra have been appropriately scaled and offset for visual 
clarity.  
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From both Raman analysis and visual inspection it is clear that, using the same 
dewaxing procedure, the low-E substrate is fully dewaxed, yet the CaF2 and Spectrosil 
substrates retain paraffin wax. Residual wax, still present on both the Spectrosil and 
CaF2 substrate, could be seen visually both macroscopically and microscopically 
(Figure 15). Its presence is confirmed by paraffin peak contributions in their spectra. 
The low-E substrate did not retain any visual paraffin wax and no paraffin peaks were 
present in the 10 spectra taken at different points along the surface of the substrate. This 
observation infers that the difference of surface chemistry, properties or morphology 
between the substrates causes low-E slides to dispel wax more readily than either CaF2 
or Spectrosil. This shows, for the first time, that substrate type has an effect on the 
dewaxing process. The difference in dewaxing between Low-E, CaF2 and Spectrosil 
slides will reflect in the spectra produced from specimen situated on these different 
substrate types through their input of paraffin contributions.  
 
Figure 15: Photographs showing microscopic Raman images at x 10 of the substrate surfaces after 
dewaxing. Wax residuals can be observed on the CaF2 and Spectrosil substrates.  
 
 
Atomic force microscopy (AFM) was used to analyse the three substrates’ 
surface composition. The AFM images of the three substrates are displayed in Figure 
16, showing the surface morphology at a nanoscopic level. The low-E substrate was 
observed to have a far smoother surface than either CaF2 or Spectrosil with an average 
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surface roughness of 1.10 nm compared to 4.76 nm and 3.88 nm respectively. Low-E 
slides are coated with a metal oxide layer [73]. This could provide an explanation for 
why their surface is far smoother than the other polished substrates.    
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Figure 16: Photographs showing AFM images of Spectrosil, CaF2 and Low-E substrates.  
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The clinical application of spectral histopathology is the primary aim of this 
research field and the ability to fit into the current clinical processes is desired. The use 
of Low-E slides has more advantages for this application than the other substrates, such 
as lower cost, larger slide size and higher levels of slide resilience. Although high 
spectral background and undefined peaks lead to a poor signal-to-noise ratio, spectra 
generated using low-E substrates still exhibit all the major peaks that are present in the 
spectra of CaF2 and Spectrosil. Further work is needed to understand the variation that 
occurs between the Raman spectra of different substrates and assess the significance of 
this impact upon clinical application.   
 
3.3 Immersion vs. Non-Immersion Raman spectroscopy 
 
Immersion and non-immersion Raman spectroscopy, using an incident 
wavelength of 785 nm, are investigated to initially assess the two techniques as 
diagnostic tools by comparison of the tissue spectra quality produced by both methods. 
 
Spectral acquisition of tissue on Low-E slides was attempted via immersion 
Raman, but produced a saturated spectral baseline. After observation of a burned hole in 
the substrate from the live video image, this has been attributed to substrate 
photodamage caused by the incident laser source. Therefore, CaF2 substrates were used 
for further Immersion Raman measurements. 
 
Figure 17 shows the averaged, raw spectra of tissue on CaF2 using immersion 
and non-immersion Raman spectroscopy. It is clear that the averaged immersion Raman 
spectrum initially has a lower spectral background, from 600 cm
-1
 to 930 cm
-1
, than the 
averaged non-immersion spectrum. It remains at a relatively stable intensity throughout 
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all the Raman shifts. The non-immersion spectrum has an intense spectral background, 
where it starts at 600 cm
-1
, but becomes dramatically less intense as the Raman shifts 
increase, without an increase in the signal-to-noise ratio of the peaks-of-interest. 
Immersion Raman produces spectra of higher signal-to-noise ratios and peaks with 
larger areas than those acquired by non-immersion Raman. The observed results give 
evidence that immersion Raman spectroscopy receives stronger Raman scatter signals 
than the standard technique.  
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Figure 17: Original spectral plot showing averaged raw spectra of 1116 immersion (48 samples from n=41 patients) acquisitions using, a x 50 objective, and 458 non-immersion 
acquisitions (18 samples from n=11 patients) using a x 60 objective from all tissue specimens on CaF2. 
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In Figure 18 the morphological differences of the same brain tissue sample can 
be observed between Raman and immersion Raman spectroscopy. The tissue analysed 
by immersion Raman analysis is saturated in deionised water prior the acquisition of 
measurements. The cells appear clearly delineated and transparent and the nucleus of 
cells can also be seen. The cells of the dry tissue are much less delineated and appear as 
a mass of cells. The heterogeneity of the cell thickness of the dry tissue causes some 
areas of the sample to look out of focus, whereas the immersed sample is made to look 
homogenous by their visual clarity throughout the tissue. The transition of the tissue 
from a dry state to a saturated state was seen through observation of the microscopic 
image in real time. The tissue was seen to absorb the water and the cells became 
visually clearer and more demarcated. Full saturation was concluded to occur after 
approximately 10 minutes when no further visual changes were detected, after this time 
Raman analysis could proceed and spectroscopic measurements acquired.  
 
The observed advantages, including visual clarity and better spectral quality, led 
to the further use of immersion Raman spectroscopy, over dry tissue techniques, for the 
analysis of the tissue samples and assessment of the ability of the technique as a 
diagnostic tool for metastatic brain cancer. 
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Figure 18: Photograph showing Raman (x 50) and immersion Raman (x60) image of brain tissue.   
 
 
3.4 532 nm vs. 785 nm laser line 
Figure 19 shows the averaged, raw spectra of tissue taken using both the 532 nm 
and 785 nm laser line. It is obvious that the baseline of the averaged spectrum taken 
using the 785 nm laser line is lower in intensity than the averaged spectrum taken using 
the 532 nm laser line. As a result of the advantage of a lower spectral background using 
the 785 nm laser line, its use was continued on tissue spectra acquisition for assessment 
of its use in spectral histopathology.  
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Figure 19: Original spectral plot showing averaged raw immersion Raman spectra of 996 acquisitions (48 samples from n=41 patients) using the 532 nm laser line and 1116 
acquisitions (48 samples from n=41 patients) using the 785 nm laser line from all tissue specimens. 
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3.5 Spectral Histopathology: Discrimination of metastatic tumours 
 
Although low-E substrates were demonstrated to aid tissue dewaxing more 
efficiently than the other substrates, CaF2 is a commonly used substrate for Raman 
spectroscopy due to the small background it produces. CaF2 was used to support tissue 
samples under spectral histopathology analysis. 
   
Figure 20 shows the averaged, vector normalised and background-subtracted 
immersion Raman spectra of normal (157 spectra from 7 patients), metastatic (668 
spectra from 31 patients) and GBM (127 spectra from 5 patients) brain tissue on CaF2 
substrates. Table 4 lists the tentative assignments of the major peaks present in these 
spectra [33, 60, 90-92].  
 
Spectral differences between these tissue types are observed at various peaks 
throughout the averaged spectra. The peak at 721cm
-1
, assigned to the C-N symmetric 
stretch (Figure 21) of choline [90, 91], is prominently observed in GBM tissue. In 
normal and metastatic tissues this peak is not present, although a 725 cm
-1
 peak 
assigned to adenine (Figure 21) is present [93]. Choline has been observed, in studies 
employing magnetic resonance spectroscopy, to increase in content in GBM tissue and 
all primary tumours. This is thought to be caused by increased cell proliferation and cell 
membrane turnover, resulting in an increased production of choline transporters and 
kinase enzymes [94, 95].  
 
Both GBM and metastatic tissues exhibit 782 cm
-1 
peaks of a considerable 
intensity in their spectra, assigned to nucleotide ring breathing [33] (Figure 21), whereas 
the peak in the normal tissue spectrum is either absent or of a much weaker intensity, 
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making it unidentifiable as a major peak. A peak at 1083 cm
-1
, assigned to the C-N 
stretch of proteins [33] is observable in the averaged spectrum of normal brain tissue yet 
appears absent from the spectra of cancerous tissue.  
 
A peak at 1263 cm
-1
, assigned to CN and CH2 vibrational modes of amide III 
[92] (Figure 21), is present in the normal tissue spectrum but is shifted to 1250 cm
-1
 and 
exhibits higher intensities in the spectra of GBM and metastatic brain tissue. Amide III 
is a component of the collagen within the tissue samples. Increased collagen in 
cancerous tissue is consistent with other Raman spectroscopy studies and is attributed to 
fibrosis association with lesion formation [96]. Additionally, women with dense breast 
tissues, which are normally associated with increased collagen, are found to have an 
elevated chance of developing breast cancer [97].  
 
The peak present at approximately 1658 cm
-1
 is attributed to the C=O stretch of 
amide I [33], and appears to be shifted in the average spectrum of metastatic tissues to a 
higher Raman shift of 1661 cm
-1
. The intensity of this peak is also decreased in both the 
cancerous spectra. This is consistent with the results of Gniadecka et al. who found 
reduced intensities of the amide I band of proteins in the spectra of melanoma. The 
changes in the amide bands between the normal and melanoma specimens are attributed 
to conformational changes to the protein structures [98].      
 
Intensity changes between spectral peaks of normal, GBM and metastatic brain 
tissue indicate alterations in specific biomolecule concentrations when the tissue is in 
different states of health. These observable spectral differences demonstrate the ability 
of Raman spectroscopy as a potential diagnostic tool for brain cancer. 
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Figure 20: Original spectral plot showing averaged immersion spectra of 127 GBM acquisitions (n=5 patients), 668 metastatic acquisitions (n=29 patients) and 157 normal brain 
acquisitions (n=7 patients). Spectra have been vector normalised, the backgrounds have been corrected using a 5th order polynomial fit and subtraction and 7 points of smoothing. 
The asterisks correspond to paraffin peaks from residual wax in the tissue. 
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Table 4: Data showing tentative biomolecular assignments of main spectral peaks. 
Raman Shift (cm
-1
) of 
peak 
Tentative assignment [33, 60, 90-92] 
620 C-C twisting mode of phenylalanine  
641 C-C twisting mode of tyrosine 
666 C-S stretching mode of cystine 
721 (only GBM) Symmetric choline C-N stretch (membrane phospholipid head)/adenine 
725 Adenine/C-S (protein)/C-H2 rocking 
756 Symmetric breathing of tryptophan  
782 Cytosine/uracil ring breathing of nucleotide 
827 DNA O-P-O, cytosine, uracil, thymine 
852 (CCH) ring breathing mode of tyrosine and C-C stretch of proline ring 
877 Proline 
888 Paraffin wax 
934 C-C stretching mode of proline and valine and α-helix protein 
backbone/glycogen 
957 Hydroxyapartite (PO4
3-
 symmetric stretching) /carotenoid/cholesterol 
1002 Symmetric ring breathing mode of phenylalanine 
1031 C-H in-plane bending mode phenylalanine  
1061 Paraffin wax 
1083 (only normal) C-N stretching mode of proteins 
1098 C-C/C-O phospholipids 
1131 Paraffin wax 
1156 C-C carotenoids, C-N stretching of proteins 
1171 Paraffin wax 
1207 Tyrosine, Hydroxyproline/tryptophan, phenylalanine (C-C6H5) 
1250 Amide III: collagen (C-H2 wag, C-N stretch)/Pyrimidine bases C, T 
1263 (only normal) Amide III: collagen (C-H2 wag, C-N stretch)/Pyrimidine bases C, T 
1294 Paraffin wax 
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1318 CH3 CH2 twisting mode of collagen/lipids 
1340 CH3 CH2 wagging mode of collagen, nucleic acids 
1389 CH3 bend 
1417 Paraffin wax 
1440 Paraffin wax 
1449 CH2 bending mode of proteins/(CH3) (CH2) collagen 
1462 Paraffin wax 
1554 C=C Tryptophan, porphyrin 
1584 Pyrimidine ring (nucleic acids) and heme protein/C=C phenylalanine 
1604 C=C in-plane bending mode of phenylalanine and tyrosine, C=C porphyrin 
1618 C=C stretching mode of tyrosine and tryptophan 
1658 Amide I (C=O stretching mode of proteins, α-helix conformation)/C=C lipid 
stretch 
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Figure 21: Chemical structures of choline, amide, nucleotide and the bases of nucleotides: adenine, 
guanine, cytosine, thymine and uracil, which contribute to peaks in the spectral differences between 
GBM, normal and metastatic brain tissue.  
Amide groupCholine
Nucleotide
Nitrogenous base
Sugar Phosphate backbone
-
-
R
Purines
Pyrimidines
Adenine Guanine
Cytosine Thymine Uracil
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It can be seen from Figure 22, that on a spectral level the data assembles 
together in their histopathological groups for GBM, metastatic and normal brain 
respectively. However, there is a degree of overlap between the groups. Details of the 
PC-DFA model and the number of spectra used can be found in Table 5. At a 95% 
confidence limit, GBM classification has a sensitivity of 95.24% and a specificity of 
36.13%, metastatic classification has a sensitivity of 95.47% and a specificity of 
81.05% and normal brain classification has a sensitivity of 90.38 % and a specificity of 
56.82%. At a 90% confidence interval GBM classification has a sensitivity of 92.86% 
and a specificity of 72.63%, metastatic classification has a sensitivity of 91.82% and a 
specificity of 90.43% and normal brain classification has a sensitivity of 88.46% and a 
specificity of 78.41%.  
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Figure 22: Original discriminant function plot showing the separation between GBM (n=5 patients) (1), metastatic (n=29 patients) (2) and normal (n=7 patients) (3) brain tissue, at 
spectral level, based on the training set (red) and test set (blue) with 95% (outer ellipse) and 90% (inner ellipse) confidence limits. 
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Table 5: Data showing the PC-DFA model details, including spectral numbers and the resulting 
sensitivities and specificities.  
 Train 
spectra 
Test 
spectra 
Confidence 
level 
Histopathological 
type 
Sensitivity 
(%) 
Specificity 
(%) 
GBM vs. 
norm vs. met 
639 316 90% GBM 92.86 72.63 
Normal 88.46 78.41 
Metastatic 91.82 90.43 
95% GBM 95.24 36.13 
Normal 90.38 56.82 
Metastatic 95.47 81.05 
Metastatic 
comparison 
449 222 95% Breast 95.74 44 
Lung 93.75 30.38 
Colon/Rectum 76.08 50 
Melanoma 97.06 20.21 
Oesophagus & 
stomach 
96.67 47.64 
primary 
comparison 
111 53 95% Breast 77.42 89.66 
Colon/Rectum 57.14 100 
Melanoma 100 55.56 
Oesophagus & 
stomach 
14.29 100 
99% Breast 87.1 86.36 
Colon/Rectum 71.43 100 
Melanoma 100 42.22 
Oesophagus & 
stomach 
42.86 100 
 
 
Figure 23 displays the discriminant function loadings plots relating to this PC-
DFA and Table 6 identifies the Raman shifts of the main peaks. The loadings contain 
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the peaks 721 cm
-1
, 725 cm
-1 
and 782 cm
-1
 which were visibly identified as being 
different in the metastatic, normal and GBM brain tissue spectra. Therefore, the 
discriminatory power of these peaks were further tested through calculation of their 
ratios to the 620 cm
-1
 peak, which appeared to be more uniform across the spectra, to 
analyse the importance of the intensity differences between the spectra.   
 
Figure 23: PC-DFA loadings plot of discriminant functions 1 and 2 from the GBM vs. metastatic vs. 
normal (Figure 9) PC-DFA model. 
 
1 
2 
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Table 6: Data showing the Raman shifts of the main peaks from the PC-DFA loadings. 
Raman Shift (cm
-1
) of PC-DFA loadings peak 
DF 1 loadings DF2 loadings 
620 721 
641 756 
666 827 
725 957 
756 1031 
782 1156 
827 1263 
852 1389 
877 1554 
934 1584 
957 1618 
1002  
1031  
1083  
1098  
1156  
1207  
1250  
1318  
1340  
1554  
1584  
1604  
1618  
1658  
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Figure 24 displays the 2D score plot of peak intensity ratios and further shows 
separation between metastatic, GBM and normal brain tissues based on the intensity 
ratios of the 620 cm
-1
 peak, which is uniform in all the spectra, to the 782 cm
-1
 peak, 
which appears absent in normal brain, and the 721 cm 
-1
 peak, present in only GBM 
tissue spectra. It can be seen that the ratios calculated from the spectra of GBM, 
metastatic and normal brain tissue clearly group together in their tissue types. Two 
outliers can be seen from the ratio graph at location (1.45, 2.19) and (1.9, 1.09), 
belonging to the normal and metastatic group, identified as patient 007 and 509 
respectively. Upon inspection of these patients’ averaged spectra, it was observed that 
they notably differed from the other averaged spectra from the same histological group 
and also from the total averaged spectra of the histological group.  
 
GBM classification has a sensitivity of 100% and a specificity of 94.44% based 
on the 721 cm
-1
 to 620 cm
-1
 ratio data above 1. Metastatic classification has a sensitivity 
of 96.55% and a specificity of 100% based on the 721 cm
-1
 to 620 cm
-1
 ratio data below 
1 and 620 cm
-1
 to 782 cm
-1
 ratio data below 5, respectively. Moreover, normal brain 
classification has a sensitivity of 85.71% and a specificity of 100% based on the 721 
cm
-1
 to 620 cm
-1
 ratio data below 1 and 620 cm
-1
 to 782 cm
-1
 ratio data above 5. The 
ratios of peaks in the low wavenumber regions, 600-800 cm
-1
, allow rapid, directed 
Raman analysis to discriminate GBM, metastatic and normal brain tissue.       
 
 
 
 
 
 
76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: 2D score plot of the 620 cm
-1
 to 782 cm
-1
 peak ratio versus the 721 cm
-1
 to 620 cm
-1
 peak ratio. Each data point is the patient average (n=≥20 spectra per specimen) from 
normal (n=7 patients), metastatic (n=29 patients) and GBM (n=5 patients) spectra that have been vector normalised and 5
th
 order polynomial subtracted. 
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It can also be observed from Figure 20 (page 59), that the averaged spectrum of 
normal tissue that the paraffin peaks (asterisked peaks) present are of a much lower 
intensity than those in the spectra acquired from metastatic and GBM tissue. This could 
be attributed to either structural or compositional differences between the tissue types 
showing a tissue effect on the dewaxing efficacy as well as a substrate effect. 
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Figure 25: Score plot of intensity measurements from the 1061 cm
-1
 peak and the 1131 cm
-1 
peak of patient averaged normal, GBM and metastatic spectra.
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Figure 25 shows the score plot of the intensities of the paraffin peaks: 1061 cm
-1
 
against 1131 cm
-1
, from patient averaged spectra. It can be seen that the paraffin peaks 
from normal brain tissue spectra generally exhibit lower intensities than the cancerous 
tissue spectra. As a result the normal brain tissue data group together at the lower 
intensity range of the score plot and the cancerous brain tissue data group together at the 
higher intensity range on the score plot. The disparity of wax retention between these 
different histological tissues could perhaps be used to tentatively highlight cancerous 
areas in the tissue and differentiate between cancerous and normal tissue. The spectra 
within the GBM group appear to be less uniform and displays paraffin peaks of both 
high and low intensities which can overlap with those from the metastatic spectra. As a 
result, it would be more challenging to differentiate between GBM and metastatic tissue 
to a reliable level and combining the two groups together, as cancerous tissue, gives a 
better indication of the disparity of dewaxing efficacy between normal and cancerous 
specimens.  
Figure 26: Bar chart of three paraffin peak intensities with standard deviation from 127 GBM 
acquisitions (n=5 patients), 668 metastatic acquisitions (n=29 patients) and 157 normal brain acquisitions 
(n=7 patients) on CaF2 substrates.    
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Figure 26 shows the standard deviations of intensity across the spectra from 
paraffin peaks 1061 cm
-1
, 1131 cm
-1 
and 1294 cm
-1
. It can be observed from the graph 
that there is a general trend for higher paraffin peak intensities in the spectra of 
metastatic and GBM tissue than in the spectra of normal tissue specimens.   
 
Li et al. [99] state that the amount of fibro-glandular and adipose tissue is 
strongly related to the risk of developing breast cancer. They explain that although no 
direct evidence has been found to link dense mammographic tissue with the increased 
chance of developing breast cancer, the obvious correlations observed have encouraged 
the use of tissue density for breast cancer monitoring. They go on to support the 
observations of this correlation through their findings that the mammograms of 
cancerous breast tissue are far denser than those of normal breast tissue [99]. The 
modification in tissue density observed between normal and cancerous tissue could 
provide an explanation for the efficiency inconsistency of the dewaxing procedure, and 
thus the variation of paraffin peak intensity between the normal brain and cancerous 
brain tissue spectra. It would appear that the denser, cancerous tissue retains paraffin 
wax better than the less dense, normal tissue.    
  
 
Figure 27 shows the averaged spectra of GBM and normal brain tissues, and 
metastatic: breast, lung, colon/rectum, melanoma and oesophagus and stomach brain 
tissues. No visible differences between the spectra of the metastases based on their 
origins are apparent.      
 
81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Original spectral plot of averaged immersion spectra: 141 breast met acquisitions (n=6), 138 colon/rectum met acquisitions (n=6), 127 GBM acquisitions (n=5), 194 lung 
met acquisitions (n=8), 102 melanoma met acquisitions (n=5), 157 normal brain acquisitions (n=7) and 93 oesophagus and stomach met acquisitions (n=4). Spectra have been vector 
normalised and offset for visual clarity. The asterisks represent the paraffin contributed peaks.  
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Figure 28 shows the PC-DFA was performed on the metastatic tissues data. It 
can be seen that, although there is a large amount of overlap between the classes, the 
tissue types generally group together showing the potential for primary cancer site 
identification from analysis of the metastatic brain tissue. Details of the PC-DFA can be 
found in Table 5. In particular, the melanoma metastases and breast metastases show the 
clearest separation from each other and the others groupings. At a 95% confidence limit 
breast met classification has a sensitivity of 95.74% and a specificity of 44.00%. 
Colon/rectum met classification has a sensitivity of 76.08% and a specificity of 50.00%. 
Lung met classification has a sensitivity of 93.75% and a specificity of 30.38%. 
Melanoma met classification has a sensitivity of 97.06% and a specificity of 20.21%. 
Oesophagus and stomach met classification has a sensitivity of 96.67% and a specificity 
of 47.64%. 
 
 Although their classification sensitivities are considerably high, the low 
classification specificities would result in a high number of false positives based on this 
PC-DFA model.  
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Figure 28: Original discriminant function plot displaying the separation of breast met (n=6 patients) (1), colon/rectum met (n=6 patients) (2), lung met (n=8 patients) (3) melanoma 
met (n=5 patients) (4) and oesophagus & stomach met (n=4 patients) (5) based on the train set (red) and test set (blue) with a 95% confidence limit represented by ellipse. 
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 PC-DFA was performed on the primary cancers spectral dataset: breast, 
melanoma, oesophagus and stomach and colon/rectum. Primary lung tissue specimens 
were not available in the biobank. Details of the PC-DFA model are displayed in Table 
5. The primary cancer tissue samples are linked samples, from the same patient as the 
corresponding metastatic tissue samples used in the metastatic tumour model. As can be 
seen in Figure 29, the tissue types separate well and crossover is only observed between 
the breast and melanoma cancers. At a 95% confidence limit breast cancer classification 
has a sensitivity of 77.42% and a specificity of 89.66%. Colon/rectum cancer 
classification has a sensitivity of 57.14% and a specificity of 100%. Melanoma cancer 
classification has a sensitivity of 100% and a specificity of 55.56%. Oesophagus and 
stomach cancer classification has a sensitivity of 14.29% and a specificity of 100%. At 
a 99% confidence limit breast cancer classification has a sensitivity of 87.10% and a 
specificity of 86.36%. Colon/rectum cancer classification has a sensitivity of 71.43% 
and a specificity of 100%. Melanoma cancer classification has a sensitivity of 100% and 
a specificity of 42.22%. Oesophagus and stomach cancer classification has a sensitivity 
of 42.86% and a specificity of 100%.  The primary cancer tissues show much better 
separation than the metastatic tissues in their PC-DFA models. Hence, the spectra 
produced from the brain metastases in this study must be comparatively different from 
those produced from their primary site cancers. Metastatic types are more spectrally 
alike than primary cancers are to each other. This may suggest a change in the 
biochemistry of the cancer cells depending on organ location and not cancer type. 
However, due to only a small number of primary tissue specimens investigated in this 
study no accurate conclusions can be made, as variations may arise from molecular 
differences between patients rather than disease.  
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Figure 29 Original discriminant function plot displaying the separation of primary breast (n=5 patients) (1), primary colon/rectum (n=1 patients) (2), primary melanoma (25 spectra 
from n=1 patients) (3) and primary oesophagus & stomach (n=1 patients) (4) cancers based on the train set (red) and test set (blue) with 99% (outer ellipse) and 95% (inner ellipse) 
confidence limits. 
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Figure 30 displays the baseline-subtracted and vector normalised, averaged 
spectra of both metastatic brain and their corresponding primary sites. From the results, 
it is observable that they spectrally vary from one another in their peak intensities. This 
supports the difference in grouping between their PC-DFA models and further suggests 
that the biomolecular composition of tissue differs between the primary sites and the 
corresponding brain metastases.    
 
A uniform difference that appears between all the metastatic brain tissue spectra 
and the primary site tissue spectra is seen in the amide I peak. In metastatic brain tissue 
spectra it peaks as high as 1667 cm
-1
, in stomach/oesophagus metastases, a higher 
Raman shift than the primary sites which peak at around 1658 cm
-1
.   
   
The averaged spectra of breast cancer tissue and the corresponding metastatic 
brain tissue appear relatively similar to one another. The main difference between these 
two groups is a peak at 700 cm
-1
 present in the metastatic brain tissue spectrum but not 
visually present in the primary site tissue spectrum.  
 
Colon cancer tissues and the metastatic brain tissues are also spectrally similar 
to each other and vary mainly through the difference in peak intensities. The primary 
site tissue spectrum exhibits much higher intensity peaks than the spectrum of 
metastatic brain tissue. The primary site tissue spectrum also displays a much more 
visually obvious peak at 666 cm
-1
 than the metastatic brain tissue spectra.  
 
The spectral difference between oesophagus and stomach cancer tissues and 
metastatic brain tissues are far more obvious than between the spectra of the other 
cancers. The most noticeable disparity between the two averaged spectra is due to the 
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peak at 1621 cm
-1
 which is much more intense in the primary site spectrum than the 
metastatic brain spectrum. Furthermore, the amide I peak, at 1658 cm
-1
 is much less 
intense in the primary site spectrum than the metastatic brain spectrum which produces 
an unusual ratio between the two peaks. This unusual ratio is only exhibited in the 
oesophagus and stomach cancer spectrum. However, the spectra of both the primary and 
metastatic site, for the other cancers exhibit similar ratios for these peaks where the 
Amide I is much more intense than the 1621 cm
-1
 peak. A peak at 796 cm
-1
 is displayed 
in the primary site spectrum of the oesophagus and stomach but is not present in the 
spectrum of metastatic brain.  
 
The spectral differences between melanoma primary site and metastatic tissue 
are between the peak intensities. The amide III peak at 1250 cm
-1
 is at a similar intensity 
to the 1340 cm
-1
 peak in the metastatic tissue spectrum. In the primary site spectrum 
there is a disparity between these two peaks with the 1340 cm
-1
 peak having a much 
higher intensity than the amide III peak. 
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Figure 30 Original spectral plot of averaged 95 primary breast acquisitions (n=5) and 96 breast met acquisitions (n=5) (top left), 22 primary colon acquisitions (n=1) and 22 
metastatic colon/rectum acquisitions (n=1) (top right), 22 primary oesophagus & stomach acquisitions (n=1) and 22 oesophagus & stomach met acquisitions (n=1) (bottom left) and 
25 primary melanoma acquisitions (n=1) and 20 melanoma met acquisitions (n=1) (bottom right). The spectra have been vector normalised, baseline corrected by 5
th
 order 
polynomial fit and subtraction, and 7 points of smoothing.    
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Chapter 4 
Conclusions 
 
Through assessments, comparing the 785 nm laser line to the 532 nm laser line 
and Raman spectroscopy to immersion Raman spectroscopy, the techniques and settings 
used for spectral histopathological analysis were tailored to optimise the quality of the 
results generated in the study. It is observed in this study that immersion Raman 
spectroscopy employing a 785 nm laser generated spectra of better overall quality, with 
higher signal-to-noise ratios. Hence, these methods and settings were used for further 
investigation into the diagnostic capabilities of Raman spectroscopy. 
 
In this study, the use of immersion Raman spectroscopy to differentiate between 
GBM, metastatic and normal brain tissue has been demonstrated using peak ratios, with 
sensitivities and specificities of 100% and 94.44%, respectively for GBM, 96.55% and 
100%, respectively for metastatic brain, and 85.71% and 100%, respectively for normal 
brain tissue.  The potential of immersion Raman spectroscopy to identify the origin site 
of the primary cancer from the analysis of brain metastases has also been observed 
through the PC-DFA model which shows separation of different metastatic brain tissue 
spectra based on their location for breast, lung, melanoma, colon/rectum and 
oesophagus and stomach. From analysis this study has identified spectral differences 
between GBM, metastatic and normal brain tissues and highlighted the main alterations 
to be attributed to the choline peak at 721 cm
-1
, present in GBM and absent in both 
metastatic and normal brain, and the nucleotide peak at 782 cm
-1
 present in metastatic 
and GBM and absent in normal brain. The ratios of these peaks were significantly 
different between the spectra of the different histopathological groups enabling 
segregation of the various tissue types. PC-DFA on the data produced sensitivities and 
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specificities for GBM classification of up to 95.24% and 72.63%, respectively. For 
metastatic classification of up to 95.47% and 90.43% were calculated, respectively. For 
normal brain classification of up to 90.38% and 78.41% were calculated, respectively. 
This analysis used the spectra across the full wavelength range that was analysed. This 
further shows that the spectra, from 400 cm
-1
 to 1800 cm
-1
, of metastatic, GBM and 
normal brain tissue are distinguishable from each other and can potentially be used to 
diagnose cancerous tissue.   
 
However, this study is based on the assumption that histopathology, employed in 
this study to diagnose the tissue specimens, has identified all the samples and their 
primary sites of origin correctly.  
 
This study also shows the influence that Raman substrates have on sample 
preparation and the resulting spectra. Spectral backgrounds of the substrates show that 
the baseline of low-E is the highest and CaF2 the lowest of the three substrates. It has 
been observed that the tissue specimens on the CaF2 and Spectrosil substrates exhibit 
paraffin peaks in their spectra whereas the tissue specimens on the low-E substrates do 
not. Throughout this investigation it has been established that CaF2 and Spectrosil 
substrates retain paraffin wax residuals after the dewaxing procedure was carried out, 
whereas low-E did not. This was attributed to the difference in surface morphology of 
the substrates causing a variation in the retention of paraffin wax. AFM of the three 
substrate types shows that low-E is smoother than either CaF2 or Spectrosil and thus 
must dispel wax more easily.  
 
It was also noted that the spectra of metastatic tissue had much larger paraffin 
peaks present than the spectra of GBM tissue and that normal tissue spectra had an even 
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smaller paraffin contribution than that of GBM. This has been attributed to the change 
of tissue density between normal tissue and cancerous tissue. The denser cancerous 
tissue seems to have an increased ability to retain paraffin wax than the less dense, 
normal tissue.   
 
Overall, this study has shown the successful use of immersion Raman 
spectroscopy as a diagnostic clinical tool for cancer and its potential for primary cancer 
origin site identification. This study has also presented the substantial influence 
substrate material has on tissue preparation methods and the outcome of spectra. 
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Chapter 5  
Future Work 
 
 There are many future studies that could be of interest and benefit to the 
advancement of this area of cancer research and other related areas. The spectral 
differences between normal brain, metastatic brain and GBM tissues need to be further 
investigated to ascertain the relevance of immersion Raman spectroscopy as a 
diagnostic technique and assess its potential use in clinical settings. The analysis of a 
larger sample size and wider variety of metastatic cancer types from different primary 
locations would be of benefit and improve the reliability of the results. Other primary 
tumours of the brain could also be studied to analyse the spectral differences between 
these tumours and metastatic lesions, and the ability to stage tumours based on their 
spectral signatures. Such studies could lead to the identification of particular 
characteristic peaks or spectral patterns capable of acting as biomarkers for metastatic 
brain cancer.  
 
 A study more closely designed for in vivo use of the technique is essential to 
assess the clinical relevance of Raman spectroscopy. Such studies could utilise deep 
Raman techniques and fibre optics.  
 
 A study could also be carried out to further identify the spectral differences 
between metastatic brain cancer and their corresponding primary cancers to ascertain a 
greater understanding of the biomolecular changes that incur between primary cancers 
and resulting metastases in the brain and possibly other organs where metastases 
frequently form.  
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 A further investigation into the identification of primary sites from metastases is 
needed. This should be carried out on a variety of metastatic tissue, not just brain, in 
order to analyse significant spectral trends that could accurately diagnose the primary 
cancers from metastatic tissues. 
 
 A study is required to further ascertain the effects spectroscopic substrates and 
tissues of different histology have on the dewaxing process of tissue samples and the 
outcome of Raman spectra. This should be carried out in order to optimise Raman 
spectroscopy and tissue preparation techniques for future work in the field of bio-
spectroscopy. 
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Appendices 
 
Appendix 1 – Poster submitted to the 7th International Conference on Advanced 
Vibrational Spectroscopy held in Kobe, Japan. 
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Appendix 2 – Poster submitted to the British Neuro-oncology society Annual meeting 
2013 held at Durham University.  
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Appendix 3 - A report entitled ‘Investigating the use of Raman and Immersion Raman 
Spectroscopy for Spectral Histopathology of Metastatic Brain Cancer and Primary Sites 
of Origin’, written based on the findings from this MSc (by research) currently under 
review by the authors for submission to ‘Analytical Methods’.  
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Abstract 
 It is estimated that approximately 13,000 people in the UK are diagnosed with 
brain cancer every year; of which 60% are metastatic. Current methods of diagnosis can 
be subjective, invasive and have long diagnostic windows. Raman spectroscopy 
provides a non-destructive, non-invasive, rapid and economical method for diagnosing 
diseases. The aim of this study was to investigate the use of Raman and immersion 
Raman spectroscopy for diagnosing metastatic brain cancer and identifying primary 
sites of origin using brain tissue. Through spectral examination, the Raman peaks at 721 
cm
-1
 and 782 cm
-1
 were identified as being the most distinct for discriminating between 
the glioblastoma multiforme (GBM), metastatic and normal brain tissue spectra. A ratio 
score plot of these peaks calculated the classification sensitivities and specificities as 
100% and 94.44% for GBM, 96.55% and 100% for metastatic brain, and 85.71% and 
100% for normal brain tissue. Principal Component-Linear Discriminant Analysis (PC-
LDA) also showed discrimination between normal, GBM and metastatic brain tissue 
spectra. We also present, for the first time, the use of Raman spectroscopy to investigate 
primary site of origin for metastatic brain cancer and any biochemical differences 
between different primary and metastatic cancer using linked samples. This study 
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revealed interesting spectral differences in the amide regions showing changes in the 
biochemistry of the metastatic brain cancer from the primary cancer 
 
Keywords: Immersion Raman, Vibrational Spectroscopy, Diagnosis, Brain Cancer, 
Metastatic  
 
Introduction 
It is estimated that a third of people in the UK will develop cancer at some point 
during their lifetimes; and approximately 50% of these will die as a result of the disease 
within five years after diagnosis [1]. Brain metastases are the most common form of 
intracranial neoplasms in adults and are predicted to develop in 20-40% of cancer 
patients [2]. It is reported that around 13,000 people in the UK are diagnosed with brain 
cancer every year, of which, 60% are metastatic tumours that have originated from 
primary cancers located outside the central nervous system [3]. All cancers have the 
potential to metastasise and their probability of doing so is influenced by their location; 
lung cancer is the most common cancer to metastasise and is responsible for 50% of all 
brain metastases, breast cancer is the second most common and accounts for 15-25%, 
melanoma accounts for 5-20%, and the remaining 5-30% are as a result of other cancers 
[4]. Identifying the site of origin of the primary tumour increases the efficiency of 
treatment and thus patient survival; however, in 15% of metastatic cases, the location of 
the primary cancer is unknown [5].  
The current method of diagnosis for brain metastases and their primary sites is 
histopathological analysis. The cancer type and the origin of the primary cancer can be 
identified based on the tissue architecture observed [6]. This method requires a trained 
neuropathologist, has a long diagnostic window, and can be subjective [7]. As well as 
these issues, disagreement amongst pathologists is reported to occur in up to 43% of 
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specimens [8]. The accurate and rapid diagnosis of disease allows early intervention of 
appropriate treatment, thus increasing life expectancy and reducing healthcare costs [9]. 
Therefore, there is a requirement for non-subjective techniques that can rapidly and 
accurately identify disease.  
Raman spectroscopy is an analytical technique that utilises the phenomenon of 
inelastic light scattering to produce characteristic spectra unique to specific samples. 
When a tissue becomes diseased, molecular changes occur, which should be reflected in 
its spectrum. The identification of spectral differences between healthy and diseased 
tissue should enable objective diagnosis of specific diseases. Raman spectroscopy is not 
significantly affected by water and thus can be used in vivo to reduce and aid biopsy 
[10]. Raman spectroscopy is also a non-destructive, rapid and economical technique, 
making it an attractive method for diagnosis [11].  
The potential of Raman spectroscopy as a diagnostic technique for diseases has 
been demonstrated by a variety of studies. Many papers have shown the ability of 
Raman spectroscopy to diagnose cancers, such as: brain cancers  using tissue on low-E 
microscope slides and CaF2 slides respectively [12, 13], lung tumours through the 
analysis of bronchial tissue sections [14],  gastric adenocarcinomas using tissue samples 
[15, 16], non-melanoma skin cancers from the analysis of tissue in vivo [17], laryngeal 
cancers from tissue at endoscopy [18], breast cancers using fresh and frozen tissue 
specimens respectively [19, 20], cervical cancers from tissue in vivo and ex vivo [21, 
22], bladder and prostate cancers from tissue sections [23, 24] and oesophagus and 
colon cancers through the analysis of snap frozen tissue on CaF2 [25]. 
Gajjar et al. reported the ability of Raman spectroscopy to differentiate between 
brain tumour and healthy brain tissue [12]. They observed successful discrimination 
between different brain tumour types in their study. They reported that metastatic brain 
tissue could be recognised from healthy brain tissue on low-E substrates based on 
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spectral peaks at: 997 cm
-1
 (phospholipids and glucose-I-phosphate), 1077 cm
-1
 and 
1446 cm
-1
 (lipids and proteins), 1241 cm
-1
 (Amide III), ≈ 1460 cm-1 (cytosine) and 1654 
cm
-1
 (Amide I) [12]. 
Tissue samples are usually fixed using formalin and impregnated with paraffin 
wax to preserve the tissue for future analysis. The addition of paraffin also provides 
support for the microtomy process, enabling the sectioning of the tissue block for 
microscopic examination. However, prior to histological and Raman analysis, tissue 
sections must undergo a dewaxing process to remove the added paraffin. This then 
allows histological staining of the tissue for pathological examination, and reduces the 
paraffin contributions in Raman spectra. Ó Faoláin et al. investigated the efficacy of 
dewaxing procedures on formalin fixed, paraffin preserved (FFPP) cervical tissue on 
glass slides [26]. They reported that dewaxing procedures employing the commonly 
used, xylene and histoclear solvents, do not completely remove all of the paraffin wax; 
they found hexane to be a much more efficient dewaxing agent [26] However it requires 
18 hours of tissue submersion and is not clinically used for dewaxing procedures, 
conventional clinical dewaxing procedures were employed here [27].  
Immersion Raman spectroscopy utilises an immersion lens which is in direct 
contact with an appropriate liquid, such as deionised water covering a sample under 
investigation. Bonnier et al. describe and successfully demonstrate the use of immersion 
Raman spectroscopy for both live cell and the first example of in vitro tissue specimens 
on CaF2, and observed an improvement in spectral quality, sample stability and the 
reduction of spectral background [28, 29]. Bonnier et al. [28, 29] demonstrated that 
fluorescence, contributing to spectral background, is only significant from sources 
producing short wavelengths of light, as proteins typically only fluoresce when sources 
producing wavelengths below 500nm are used and therefore, the background 
contribution seen from spectra acquired when using 785 nm lasers should not be 
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attributed to fluorescence, but to morphology dependant scattering of the incident light, 
and Raman lines that cause non-collimated entry into the spectrometer as stray light. 
The exchange of a tissue/air interface with a tissue/liquid interface results in more 
uniform refractive indices, thus reducing this level of stray light, and in turn, the 
intensity of the spectral background. Submerging the sample in liquid also protects the 
tissue specimen from photo-damage; enabling more powerful lasers of shorter 
wavelengths to be used, longer acquisition times and higher numbers of accumulations 
to be employed hence, improving spectral quality.  
We present a comparison of Raman and immersion Raman recorded spectra, 
with a study highlighting the use of immersion Raman spectroscopy for the rapid 
diagnosis of site of origin of metastatic brain tumours. Vibrational spectroscopy has the 
ability to revolutionise the clinical environment allowing for increased efficiency within 
the diagnostic regime with corresponding decreases in mortality, morbidity and 
economic impact upon the health services [30]. 
 
Experimental 
Study participants 
Tissue sections were cut using a microtome. Parallel tissue sections of 4 µm in 
thickness were cut for glass microscope slides and 10 µm for CaF2 (Crystran, UK) 
substrates. Tissue was obtained from formalin fixed paraffin preserved (FFPP) tissue 
blocks from the Brain Tumour North West (BTNW) bio-bank under ethical approval 
(BTNW/WRTB 13_01). Patient data consisted of histological information, patient 
gender, and date of birth and origin of metastasis/histological subtype. A total of 48 
tissue specimens were obtained from 41 different patients. Tissue consisted of normal 
brain samples (n=7), glioblastoma multiforme (GBM) brain samples WHO (World 
Health Organisation) grade IV (n=5), metastatic brain samples (n=29) and primary 
108 
 
cancer tissue samples (n=7). Table 1 displays further information about the tissue 
specimens.  
 Table 1 Patient details with histological subtype and metastatic origin.    
BTNW no. Gender DOB Origin of Metastasis/histological 
subtype 
119 F 26/06/1963 Breast (met and primary site) 
707 F 07/08/1945 Breast (met and primary site) 
756 F 15/03/1957 Breast (met and primary site) 
888 M 25/11/1948 Colon/rectum (met and primary site) 
985 M 05/02/1933 Melanoma (met and primary site) 
988 M 30/12/1949 Oesophagus & stomach (met and 
primary site) 
1001 F 20/12/1944 Lung (met only) 
690 / 1012 F 25/10/1960 Breast (met and primary site) 
1004 F 03/09/1956 Breast (met only) 
998 / 1010 M 25/07/1946 Colon (met only) 
1020 F 05/06/1948 Breast (met only) 
2 F 28/10/1937 GBM 
3 F 22/09/1981 GBM 
4 M 08/12/1942 GBM 
5 F 29/10/1958 GBM 
7 M 14/04/1939 Normal Brain 
10 F 13/06/1929 GBM 
78 F 24/09/1955 Lung (met only) 
106 F 14/02/1965 Normal Brain 
132 F 24/06/1943 Normal Brain 
136 F 25/09/1956 Normal Brain 
137 M 26/04/1944 Colon/rectum (met only) 
164 M 10/04/1954 Oesophagus & stomach (met only) 
184 F 21/11/1948 Lung (met only) 
215 M 21/01/1973 Lung (met only) 
274 M 12/07/1940 Colon/rectum (met only) 
295 F 12/06/1936 Lung (met only) 
358 M 08/05/1935 Melanoma (met only) 
409 F 08/08/1925 Colon/rectum (met only) 
444 M 30/01/1978 Normal Brain 
509 M 11/02/1930 Melanoma (met only) 
517 F 05/06/1955 Lung (met only) 
521 M 18/01/1949 Oesophagus & stomach (met only) 
562 F 12/03/1953 Lung (met only) 
567 F 09/04/1947 Melanoma (met only) 
668 F 30/08/1943 Colon/rectum (met only) 
678 F 13/11/1961 Normal Brain 
688 F 15/06/1965 Melanoma (met only)  
694 M 18/09/1951 Lung (met only) 
721 F 04/01/1976 Oesophagus & stomach (met only) 
772 M 21/09/1972 Normal Brain 
 
Dewaxing and Haematoxylin and Eosin staining of tissue 
Tissue sections on the microscope slides were stained with Haematoxylin and 
Eosin (H&E) for histological examination So as to remove the paraffin, tissue sections 
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were de-waxed through 2 x 5 minute baths of Histoclear followed by 2 x 5 minute baths 
of ethanol. Prior to H&E staining, tissue sections were washed in distilled water for 5 
minutes after de-waxing. Sections were then bathed in haematoxylin for 5 minutes and 
washed in warm tap water to allow the nuclei to turn blue. The sections were then 
covered in eosin for 4 minutes and washed off with distilled water. Finally, the tissue 
sections were dehydrated in 2 x 5 minute baths of ethanol and cleared in 2 x 5 minute 
baths of Histoclear tissue sections were protected and preserved through the application 
of Histomount and a coverslip. The sections were then microscopically examined in 
order to identify the metastatic sites present in the tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Microscopic images of H&E stained tissue sections of normal brain, metastatic brain, primary 
sites and GBM brain WHO grade IV (x 100). Scale bar represents 50 microns. 
 
Figure 1 shows the microscopic images of the H & E stained tissue samples at x 
100 magnification. It can be observed that normal, metastatic and GBM brain tissue 
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architecturally differ from one another, with differences also being observed between 
the differing metastatic types. 
 
Tissue section preparation for Raman spectroscopic analysis 
 The tissue sections on the CaF2 substrates also needed to be de-waxed prior to 
Raman analysis, in order to reduce the paraffin peak contributions in the spectra. The 
de-waxing procedure consisted of 3 x 5 minute baths of Histoclear followed by 3 x 5 
minute baths of ethanol. The sections were left to air dry for 30 minutes, placed in a 
Petri dish and stored in a desiccator until spectroscopic analysis. 
  
Raman spectroscopy instrumentation and analysis 
Spectroscopic measurements were carried out on a Horiba Jobin-Yvon LabRAM 
HR800 spectrometer. An air cooled CLDS point mode diode 785 nm laser with a single 
edge filter (cut off to 100 cm
-1
)
 
and an output power of 300mW was used to acquire 
spectra; which was used with a grating of 300 gr/mm and blazed at 1000 nm. Non-
immersion point spectra were acquired using a 0.9 numerical aperature (x 100) 
(MPlanN) objective and immersion point spectra were acquired using a 0.75 numerical 
aperature (x 60) objective (LUMPlanFLN, Olympus). The confocal hole was set at 100 
µm for 785 nm spectral collections. The detector used was an Andor electromagnetic 
(EM) charged coupled device (CCD). A video camera within the Raman system was 
used to take images of the specimens.  
The instrumentation was calibrated before operation to silicon at the spectral line 
of 520.8 cm
-1
. Spectra were acquired using the 785 nm laser at 100% exposure for 30 s 
and accumulated twice, with both the immersion and non-immersion objectives. A total 
of 1574 spectra were generated through the production of 20 spectra from three to five 
areas on each tissue sample, ensuring a representative area was used to gather data. 
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Immersion Raman spectroscopy was carried out by submerging the tissue sample in 
deionised water for spectral collection.  
 
Data pre-processing and multivariate analysis  
Pre-processing and multivariate analysis was carried out on the raw data using 
LabSpec 6 spectroscopy software suite (HORIBA Scientific) and MATLAB version 
7.11.0 (R2010b) (The MathWorks, Inc., USA) using in-house written software. Pre-
processing methods were kept to a minimum to enable better reproducibility; data were 
background subtracted through the application of a fifth order polynomial and smoothed 
using 7 point smoothing (Labspec 6) and vector normalised. Paraffin peaks were 
removed from the spectra for multivariate analysis at the following wavenumbers: 882 
cm
-1
 - 912 cm
-1
, 1051 cm
-1
 - 1071 cm
-1
,  1115 cm
-1
 - 1143 cm
-1
, 1163 cm
-1
 – 1187 cm-1, 
1284 cm
-1
 – 1305 cm-1 and 1407 cm-1 – 1501 cm-1. Multivariate analysis was then 
carried out on the data set using PC-DFA.   
Principal component analysis (PCA) is an unsupervised multivariate algorithm 
used to find spectral differences between recorded spectra. Being unsupervised means 
that the algorithm has no priori information on the grouping of the recorded spectra, 
PCA can only find orthogonal dimensions of spectral variance. One advantage to PCA 
is that can be used to reduce the dimensionality of the dataset prior to discriminate 
classification algorithms, such as Linear Discriminant Analysis (LDA). Without 
dimension reduction, LDA can overfit, producing over generous classification results 
based on random errors or noise, and not on the relationships between the recorded 
spectra. LDA is a supervised technique requiring prior knowledge of the group classes 
beforehand. LDA then finds the best linear hyperlane between the class groups at each 
variable dimension, maximising the intergroup variance and minimising the intragroup 
variance. The PC-LDA models created were tested using cross-validation, partitioning 
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the data matrix into two sets (training set and test set). One third of the original data set 
was randomly removed while the remaining training set data is used to build the 
classification model. The classification model is then tested using the removed (blind) 
test set spectra [31, 32]. The performance of the model is judged on how well the 
model, built using the training set, predicts the new and previously unseen test set data. 
PC-LDA model performance was judged through the percentage of test set spectra 
correctly classified (%CC) and spectra classification sensitivities and specificities based 
on the confidence ellipses plotted (95% (outer ellipse) and 90% (inner ellipse)). This 
study investigates three different PC-LDA models.  
 
Results and Discussion     
Raman and Immersion Raman spectroscopy comparison  
The averaged raw spectra of all tissue samples on CaF2 using immersion and 
non-immersion Raman spectroscopy are shown in Figure 2. It is clear that the averaged 
immersion Raman spectrum has an initial lower spectral background than the averaged 
non-immersion spectrum in the 600 cm
-1
 to 930 cm
-1
 spectral range, which remains at a 
relatively stable intensity throughout. Immersion Raman also produces better delineated 
peaks with larger areas than spectra acquired by non-immersion Raman. Therefore, due 
to the advantage of better spectral quality, immersion Raman spectroscopy was chosen 
over standard techniques to analyse its potential as a diagnostic tool for metastatic brain 
cancer and its ability to identify primary cancer sites of origin.   
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Figure 2 Immersion Raman average spectrum produced through averaging 1116 immersion acquisitions 
using a x 50 objective. Non-immersion averages spectrum was produced using 458 non-immersion 
acquisitions using a x 60 objective.  
 
Spectral Histopathology: 
Cancer vs. Metastatic Tumours vs. Non-Cancer 
The averaged, vector normalised and background-subtracted immersion Raman 
spectra of normal (157 spectra from 7 patients), metastatic (668 spectra from 31 
patients) and GBM (127 spectra from 5 patients) brain tissue on CaF2 substrates are 
displayed in Figure 3. Table 2 lists the assignments of the major peaks present in 
recorded spectra, based on literature [14, 25, 33-35]. Spectral differences between these 
tissue types are observed at the various peaks throughout the averaged spectra. The peak 
at 721cm
-1
, assigned as the C-N symmetric stretch of choline [33, 34], is prominently 
observed in GBM tissue. In normal and metastatic tissue this peak is not present, 
although a 725 cm
-1
 peak, assigned to adenine is present [36] (Figure 3). Choline 
content has been observed to increase in GBM tissue and all primary tumours through 
magnetic resonance spectroscopy; thought to be caused by increased cell proliferation 
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and cell membrane turnover, resulting in an increased production of choline transporters 
and kinase enzymes [37]. 
 
GBM and metastatic tissue both exhibit 782 cm
-1 
peaks of a considerable 
intensity in their spectra, assigned to nucleotide ring breathing [25], whereas the peak in 
the normal tissue spectrum is much weaker and is not easily identifiable in the spectra. 
A peak at ~1081 cm
-1
, assigned to PO2
−
 symmetric stretching (nucleic acids) [38], is 
observable in the averaged spectrum of normal brain tissue yet appears absent from the 
spectra of cancerous tissue (Figure 3).   
 
An amide III peak is present at 1263 cm
-1
 [35] in the normal tissue spectrum but 
for GBM and metastatic brain tissue spectra, the peak has been shifted to 1250 cm
-1
, 
possibly as a result of peak broadening, or changes in hydrogen bonding. As well as the 
shift, there is a noticeable increase in amide III peak intensity from the GBM and 
metastatic brain average spectra, when compared to normal tissue spectrum. As the 782 
cm
-1
 has previously associated with ring breathing vibrations of nucleic acids [39] the 
increase in intensity from the 782 cm
-1
 and may suggest an increase in cellular density 
from the cancerous tissue. The increase in intensity from the amide III band may well be 
in agreement with this, showing an increase in cellular proteins as a result of increased 
cell mass in the tissue.  
 
The peak present at approximately 1658 cm
-1
, attributed to the C=O stretch of 
amide I [25] appears to be shifted in the average spectrum of metastatic to a higher 
Raman shift of 1661 cm
-1
. The intensity of this 1658 cm
-1
 peak is also decreased in both 
the cancerous spectra. This is consistent with the report of Gniadecka et al., who found 
reduced intensities of the amide I band of proteins in the spectra of melanoma. The 
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changes in the amide bands between the normal and melanoma specimens are attributed 
to conformational changes to the protein structures [40]. 
It can also be observed from the averaged spectrum of normal tissue that the 
paraffin peaks (asterisked peaks) present are of a much lower intensity than those in the 
spectra of metastatic and GBM tissue. This could be attributed to either structural or 
compositional differences between the tissue types showing a tissue effect on the 
dewaxing efficacy [27].   
 
Figure 3 GBM, Metastatic and normal brain tissue average spectrums, recorded using immersion Raman 
spectroscopy. The GBM spectrum was created from averaging 127 GBM acquisitions, the Metastatic 
from 668 metastatic acquisitions and the normal brain spectrum from 157 normal brain acquisitions. 
Spectra have been vector normalised, the backgrounds have been corrected using a 5th order polynomial 
fit and 7 points of smoothing. The asterisks correspond to paraffin peaks from residual wax in the tissue. 
 
Table 2 Bio-molecular assignments of main spectral peaks.  
Raman Shift (cm
-1
) of peak Tentative assignment [14, 25, 33-35, 38] 
524 S-S stretch in proteins 
550 Tryptophan/cytosine, guanine 
620 C-C twisting mode of phenylalanine  
641 C-C twisting mode of tyrosine 
666 C-S stretching mode of cystine 
721 (only GBM) Symmetric choline C-N stretch (membrane phospholipid head)/adenine 
725 Adenine/C-S (protein)/C-H2 
756 Symmetric breathing of tryptophan  
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782 
805 
Cytosine/uracil ring breathing of nucleotide 
A-DNA [38] 
827 DNA O-P-O, cytosine, uracil, thymine 
852 (CCH) ring breathing mode of tyrosine and C-C stretch of proline ring 
870 Proline 
888 
925 
Paraffin wax 
C-C stretching mode of proline [38] 
934 C-C stretching mode of proline and valine and α-helix protein backbone/glycogen 
957 Hydroxyapartite (PO4
3-
 symmetric stretching) /carotenoid/cholesterol 
1002 Symmetric ring breathing mode of phenylalanine 
1031 C-H in-plane bending mode phenylalanine  
1061 Paraffin wax 
1081 (only normal) PO2
−
 symmetric stretching (nucleic acids) [38] 
1098 C-C/C-O phospholipids 
1131 Paraffin wax 
1156 C-C carotenoids, C-N stretching of proteins 
1171 Paraffin wax 
1207 
1234 
Hydroxyproline, tyrosine/tryptophan, phenylalanine (C-C6H5) 
Antisymmetric phosphate stretching [38] 
1250 Amide III: (β-sheet, protein) [38] 
1263 (only normal) Amide III: (α-helix, protein) [38] 
1294 Paraffin wax 
1318 CH3 CH2 twisting mode of collagen/lipids 
1340 CH3 CH2 wagging mode of collagen, nucleic acids 
1389 
1397 
CH3 bend 
CH3 bending due to methyl bond in the membrane [38] 
1417 Paraffin wax 
1440 Paraffin wax 
1449 CH2 bending mode of proteins/(CH3) (CH2) collagen 
1462 Paraffin wax 
1554 C=C Tryptophan, porphyrin 
1578 Guanadine, adenine, TRP (protein) 
1584 Pyrimidine ring (nucleic acids) and heme protein/C=C phenylalanine 
1604 C=C in-plane bending mode of phenylalanine and tyrosine, C=C porphyrin 
1618 C=C stretching mode of tyrosine and tryptophan 
1658 
1670 
Amide I (C=O stretching mode of proteins, α-helix conformation)/C=C lipid stretch 
Amide I (Proteins with β-sheet conformational structures) 
 
The mean spectral intensity changes between spectral peaks of normal, GBM 
and metastatic brain tissue (Figure 3) indicate alterations in specific biomolecule 
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concentrations when the tissue is in different states of health. These observable spectral 
differences demonstrate the ability of Raman spectroscopy as a potential diagnostic tool 
for brain cancer.  
 
 
 
Figure 4 (a) LDA scores plot showing the separation of GBM (blue), metastatic (green) and normal 
brain tissue (black) spectra. Training spectra displayed with symbols filled and test spectra un-filled, 95% 
(outer ellipse) and 90% (inner ellipse) confidence limits are also shown; PC-LDA training model created 
using the first 12 PCs, which achieved a %CC score of 72% (b) LDA scores plot of the same data used in 
(a) but with the spectra averaged. The 20 spectra recorded from each patient tissue sample were split into 
4 and averaged. The training model was created using the first 8 PCs and achieved a % CC score of 97%. 
(a) 
(b) 
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As a result of there being spectral differences between GBM, Metastatic and 
normal brain tissue mean spectra (Figure 3), the recorded spectra were investigated 
using PC-LDA to see if linear separation boundaries could be found between the spectra 
recorded from the different tissue types in multidimensional space (Figure 4). Figure 4 
shows a LDA scores plot (LDA1 vs. LDA2) of spectra recorded from GBM, Metastatic 
and normal brain tissue using immersion Raman spectroscopy. Although complete 
separation of the different tissue type spectra is not seen in the LDA scores plot (a 
degree of overlap seen between the different groups), there is some separation between 
spectra recorded from all three tissue types. The majority of GBM and normal brain 
tissue spectra are separated from Metastatic tissue spectra along the LDA 1 axis, and the 
majority of normal brain tissue spectra can be discriminated from GBM spectra along 
the LDA 2 axis. However, it can be seen in Figure 1 that all tissue types have some 
degree of tissue heterogeneity, with some Metastatic tissue types and GBM tissue being 
very heterogeneous. The heterogeneous nature of GBM tissue is said to be due to areas 
of necrosis found in the tissue surrounded by pseudopalisades and microvascular 
hyperplasia, believed to be instrumental in the accelerated growth of GBM [41]. By 
investigating different areas on each tissue sample with Raman spectroscopy there is the 
possibility that non-cancerous tissue chemistry will be captured when investigating very 
heterogeneous cancerous tissue. This is possible reflected in Figure 4 (a), which shows 
that both Metastatic and GBM tissue spectra have some overlap with normal tissue 
spectra. Therefore, the spectra used for Figure 4 (a) was split into smaller groups and 
averaged (The 20 spectra recorded from each patient tissue sample were split into 4 and 
averaged). This produced the LDA model displayed in Figure 4 (b), which now shows 
good separation between all three classes of tissue spectra; producing a classification 
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model performance score of 97%CC. Details of both PC-LDA models created in Figure 
4 can be found in Table 3. 
 
Figure 5 displays the LDA loadings plots relating to the LDA scores plot in Figure 4 
(b). Table 4 identifies the Raman shifts from the LDA 1 and 2 loading plots which are 
responsible for distinguishing normal, Metastatic and GBM tissue spectra. The LDA 1 
axis separates the Metastatic tissue spectra from the rest. The main peaks in the LDA 1 
loading plot included the 718, 925, 1250, 1400 and 1670 cm
-1
 Raman bands associated 
with symmetric choline C-N stretch (membrane phospholipid head)/adenine, C-C 
stretching mode of proline, Amide III band, CH3 bending mode due to methyl bond in 
the membrane and the Amide I C=O stretching mode of β-sheet structural proteins 
respectively. These spectral differences are in agreement with the mean spectra and 
show the Metastatic tissue spectra to have reduced intensities from the 718 and 925 cm
-1
 
peak’s, and increased intensities from the 1250 1400, and 1670 cm-1 peaks when 
compared to the tissue spectra recorded from the GBM and normal tissue. The LDA 2 
axis in Figure 4 (b) separates the majority of GBM and Metastatic spectra from normal 
tissue spectra. The main peaks in the LDA 2 loading plot included the 719, 780/805, 
1078, 1234, 1268, 1653, 1672 cm
-1
 Raman bands associated with symmetric choline C-
N stretch, cytosine/uracil ring breathing of nucleotide/A-DNA, PO2 symmetric 
stretching (nucleic acids), antisymmetric phosphate stretching, Amide III: (α-helix, 
protein), Amide I (C=O stretching mode of proteins, α-helix conformation) and the 
Amide I C=O stretching mode of β-sheet structural proteins respectively. The loading 
peaks at 1235 and 1268 are in agreement with the mean spectral differences, which 
show the Amide III peak in the cancerous spectra to shift from 1268 cm
-1
, associated 
with α-helix protein, to a lower frequency associated with β-sheet protein. The LDA 2 
loading plot and mean spectral comparisons also show the cancerous spectra to have 
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reduced intensity from the Amide I α-helix peak when compared to the normal tissue 
spectra, while the cancerous spectra also show increased intensity at ~1670 cm
-1
, 
associated with Amide I proteins with β-sheet structural conformations. This may 
suggest a link between protein secondary structure content and cancerous tissue. 
Yamada et al. also showed β-sheet protein levels to increase significantly when 
investigating necrotic areas of murine carcinoma using FT-IR microspectroscopy. The 
increase in β-sheet protein levels coincided with a sharp decrease in α-helix protein 
levels, in agreement with our results [42]. It can also be seen from the Figure 5 (b) that 
the cancerous tissue spectra have increased intensity from peaks associated with nucleic 
acids and DNA structures. As previously described, the increase intensity from nucleic 
acid structures may suggest an increase in cellular density from the cancerous tissue, in 
agreement with increased cell proliferation.  
 
Table 3 PC-LDA model details, including spectral numbers and the resulting sensitivities and 
specificities. 
 
 
Train 
spectr
a 
Test 
spectr
a 
Confidence 
level 
Histopathological 
type 
Sensitivit
y (%) 
Specificit
y (%) 
GBM vs. 
norm vs. 
met 
639 316 90% GBM 90.48 22.26 
Normal 91.89 88.30 
Metastatic 98.08 59.09 
95% GBM   
Normal   
Metastatic   
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Figure 5 (a) PC-LDA loading plot of the LDA 1 separation boundary produced in Figure 4 (b) (pink) 
(upper curves) and mean spectra (lower curves), GBM (blue), metastatic (green) and normal tissue 
spectra (black) (b) PC-LDA loading plot of the LDA 2 separation boundary produced in Figure 4 (b). 
 
 
  
 
(a) 
(b) 
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LDA1 loading bands LDA2 loading bands 
~Negative Loading 
Band Position (cm
-1
) 
~Positive Loading 
Band Position (cm
-1
) 
~Negative Loading 
Band Position (cm
-1
) 
~Positive Loading 
Band Position (cm
-1
) 
524 
642 
718 
925 
1200 
 
1010 
1250 
1402 
1670 
642 
719 
780 
805 
998 
1234 
1338 
1375 
1578 
1613 
1673 
550 
869 
1078 
1268 
1653 
 
Table 4 Spectral differences causing the separations seen in Figure 4 (b). 
 
From the mean spectral differences (Figures 3 and 5) it can be visibly seen that 
the average normal brain tissue spectrum has a low intensity from the 782 cm
-1
 peak, 
when compared to the average GBM and Metastatic spectra. It can also be seen that the 
average GBM mean spectrum has a much greater intensity in the 721 cm
-1
 peak than the 
average normal tissue and metastatic spectrums. As a result, a 2D scores plot was 
produced based on the intensity ratios between the 721/782 cm
-1
 peaks and the 620 cm
-1
 
peak (620 cm
-1
 peak intensity was relatively uniform in all the recorded spectra) (Figure 
6). Figure 6 shows the 721 and 782 cm
-1
 peaks to be significant discrimination markers 
for GBM, Metastatic and normal tissue spectra, with average GBM, Metastatic and 
normal tissue spectra clearly grouped in the 2D scores plot. This shows that the 721 and 
782 cm
-1
 peaks could potentially be markers for diseased tissue therefore, the 
monitoring of these peak intensities through Raman spectroscopy may aid the early 
diagnosis of disease. However, Figure 6 does show two spectra which cannot be 
grouped with their representative class, identified as patient 007 and 509, belonging to 
the normal and metastatic group respectively. Upon visual inspection of the spectra, it 
was observed that they notably differed from the total averaged spectra for their tissue 
types. This could potentially be a result of tissue misclassification.  
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Primary site analysis 
Raman spectra were also recorded from tissue representative of primary cancers 
(breast, melanoma, oesophagus and stomach and colon/rectum) and patient averaged. 
The primary cancer tissue samples are linked samples (from the same patient) of 
corresponding metastatic tissue samples in the metastatic tumour model. As before, PC-
LDA was performed on the spectra recorded from the tissue samples using immersion 
Raman spectroscopy. The LDA scores plot (Figure 7) shows that spectra recorded from 
the colon/rectum (blue) and oesophagus & stomach cancerous tissue (green) have some 
good separation from the remaining spectra. Less clear is the separation of the primary 
breast and melanoma tissue spectra which are shown to be spectrally similar. This may 
suggest that the tissue architecture of both primary breast and melanoma tissue is 
similar. 
Figure 6 2D score plot of the 620 cm
-1
 to 782 cm
-1
 peak ratio versus the 721 cm
-1
 to 620 cm
-1
 peak ratio. 
Each data point is the spectral patient average. 
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Figure 7 LDA scores plot of average spectra recorded from primary breast (black), primary colon/rectum 
(blue), primary melanoma (red) and primary oesophagus & stomach (green) cancerous tissue. Training 
spectra displayed with symbols filled and test spectra un-filled, 95% (outer ellipse) and 90% (inner 
ellipse) confidence limits are also shown; training model created using the first 12 PCs and achieved a % 
CC score of 72%. 
 
 
 
 
Train 
spectr
a 
Test 
spectr
a 
Confidence 
level 
Histopathological 
type 
Sensitivit
y (%) 
Specificit
y (%) 
Metastatic 
comparison 
  90% Breast 89.29 85.71 
Lung 60.00 72.22 
Colon/Rectum 92.31 60.78 
Melanoma 80.00 83.33 
Oesophagus & 
stomach 
87.50 54.17 
Primary 
comparison 
111 53 90% Breast 89.29 85.71 
Colon/Rectum 100 54.76 
Melanoma 71.43 38.90 
Oesophagus & 
stomach 
85.71 100 
Table 5 PC-LDA model details, including spectral numbers and the resulting sensitivities and 
specificities. 
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Analysis of site of origin 
Figure 7 shows that the identification of spectra recorded from some primary cancers is 
possible using multivariate classification algorithms. As the origins of metastatic brain 
tissue are determined from the tissue architecture observed, it should also be possible to 
determine metastatic brain tissue origins from the spectra recorded. Therefore, PC-LDA 
was also performed on the metastatic tissue data with the LDA scores plot displayed in 
Figure 8. As with the data used in Figure 4 (b), the 20 spectra recorded from each 
patient tissue sample were split into 4 and averaged. The LDA scores plot in Figure 8 
shows that although there is some overlap between the spectra recorded from each type 
of brain metastases, there is some separation between metastatic breast (blue), 
melanoma (red), oesophagus & stomach (black) and colon/rectum (green)/lung (cyan) 
spectra. As spectra recorded from both metastatic colon/rectum and lung tissue almost 
overlap in LDA scores space, this may suggest that the different tissue types have 
similar tissue architecture. The spectral similarities may also be due to not enough 
spectra being recorded from the different tissue types, and as a result, spectra recorded 
from the three different sites of each patient sample have not been able to capture the 
differing tissue architecture which would discriminate between the two. However, it 
may also be possible that that the movement of metastatic cancer from primary sites to 
the brain effects the biochemistry of the cancers, with all metastatic cancer found in the 
brain becoming biochemically similar due to their new environment. One of the reasons 
for this could be that the movement of metastatic cancer from primary sites to the brain 
effects the biochemistry of the cancers, with all metastatic cancer found in the brain 
becoming biochemically similar due to their new environment. This would suggest that 
biochemical differences between primary cancers are generally a result of the organ 
location and not the cancer type. 
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Figure 8 LDA scores plot of average spectra recorded from metastatic breast (blue), colon/rectum met 
(green), lung met (cyan) melanoma met (red) and oesophagus & stomach met (black). Training spectra 
displayed with symbols filled and test spectra un-filled, 95% (outer ellipse) and 90% (inner ellipse) 
confidence limits are also shown; training model created using the first 9 PCs and achieved a % CC score 
of 63%.  
 
 
  
 
(a) (b) 
(1) 
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Figure 9 (a) Mean spectral comparisons of primary (blue) and Metastatic brain tissue (black) (b) PCA 
comparisons of primary and Metastatic brain tissue recorded spectra (2d PCA scores plot displaying the 
best separation between Primary and Metastatic tissue). The spectra have been vector normalised, 
baseline corrected by 5
th
 order polynomial fit and subtraction, and 7 points of smoothing (1) Primary 
Breast spectra vs. Met Breast tissue spectra (2) Primary Colon/Rectum spectra vs. Met Colon/Rectum 
tissue spectra (3) Primary Melanoma vs. Met Melanoma tissue spectra (4) Primary Oesophagus and 
Stomach spectra vs. Met Oesophagus and Stomach tissue spectra. 
 
 
 
(2) 
(3) 
(4) 
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Spectral analysis of primary site and corresponding brain metastasis  
Figure 9 (a) displays the baseline-subtracted averaged spectra of both Metastatic 
brain and their corresponding primary sites. It is observable from Figure 9 (a) that the 
Metastatic spectra (black) from the different sites of primary origin all look similar, 
whereas the same cannot be said from the primary cancer spectra (blue), with primary 
Colon/Rectum, Melanoma and Oesophagus and Stomach tissue spectra all showing 
mean spectral differences when compared against their corresponding primary sites. 
This supports the theory that the movement of metastatic cancer from primary sites to 
the brain affects the biochemistry of the cancers, with all metastatic brain tissue spectra 
having similar chemistry when in the brain. However, the mean breast cancer tissue 
spectrum and the corresponding metastatic brain tissue spectrum appear relatively 
similar to one another. The PCA scores plot also shows no separation between the 
primary and Metastatic breast spectra therefore, suggesting that there is no real change 
from primary and Metastatic breast tissue. The spectral differences between 
Colon/Rectum cancer tissue and the metastatic brain tissue are not large and vary 
mainly through differences in peak intensities. The primary site tissue spectrum exhibits 
much higher intensity peaks than the spectrum of metastatic brain tissue. The spectral 
differences between oesophagus and stomach tissue and metastatic brain tissue are far 
more obvious than between the spectra of the other cancers. The most noticeable 
disparity between the two average spectra is due to the peak at 1621 cm
-1
, which is 
much more intense in the primary site spectrum than the metastatic brain spectrum. 
Furthermore, the amide I peak, at 1658 cm
-1
, is much less intense in the primary site 
spectrum than the metastatic brain spectrum which produces an unusual ratio between 
the two peaks. Also, a peak at ~796 cm
-1
 is displayed in the primary site spectrum but is 
not present in the spectrum of metastatic brain. For melanoma tissue, the spectral 
differences between melanoma primary site and metastatic tissue are primarily due 
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spectral differences seen from the amide I peak, the amide III and peaks present 
between 850 - 950 cm
-1
.  
    
Conclusion 
In this study, we have demonstrated the use of immersion Raman spectroscopy 
to differentiate between GBM, metastatic and normal brain tissue with sensitivities and 
specificities of 100% and 94.44% respectively for GBM, 96.55% and 100% 
respectively for metastatic brain, and 85.71% and 100% respectively for normal brain 
tissue, based on the intensity ratios between the 721/782 cm
-1
 peaks. This shows that the 
Raman spectral peaks at 721 and 782 cm
-1
, primarily associated with the symmetric C-
N stretch of choline and the cytosol/uracil ring breathing of nucleotides respectively, 
may be possible spectral biomarkers for the discrimination of normal, GBM and 
Metastatic tissue. As well as this, PC-LDA was performed on the tissue spectra 
producing good separation of GBM, Metastatic and normal tissue spectra, again 
highlighting the potential of the analytical technique for the classification of cancerous 
tissue. As well as investigating GBM, Metastatic and normal tissue spectra, this study 
has also been able to distinguish some of the different primary site cancerous tissue and 
the different Metastatic brain cancerous tissue, based on the Raman spectra recorded. 
Being able to able to distinguish Metastatic brain tissue origins based on recorded 
Raman spectra, coupled with supervised multivariate analysis, would be non-subjective, 
therefore, the analytical technique could be used as a qualitative tool alongside 
neuropathology for disease diagnosis. For the first time the chemistry of Metastatic 
brain and their corresponding primary site tissue have also been investigated in this 
study by Raman spectroscopy, with primary Colon/Rectum, primary Melanoma and 
primary Oesophagus and Stomach tissue all being separated from their representative 
Metastatic brain tissue in PCA scores space, plus, significant mean spectral differences 
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were observed. Interestingly, this suggests that in some cases, that the movement of 
metastatic cancer from primary sites to the brain effects the biochemistry of the cancers, 
with metastatic cancerous tissue found in the brain becoming biochemically similar due 
to the new environment.                
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Appendix 4 - A manuscript submitted to ‘Analyst’ entitled ‘Effect of Substrate Choice 
and Tissue Type on Tissue Preparation for Spectral Histopathology’ written based on 
findings during this MSc (by research).  
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Dear Sir or Madam 
 
Please accept this as a cover letter for my submission of a research paper entitled “Effect of 
Substrate Choice and Tissue Type on Tissue Preparation for Spectral 
Histopathology” 
 
This paper reports, for the first time, the influence of substrate choice and tissue type on the 
sample preparation of tissue for the dynamic field of spectral histopathology. This is truly a 
timely manuscript as there is much debate within the field concerning substrate choice. We 
show results describing a novel phenomenon of substrate interaction with paraffin that has 
previously not been reported elsewhere and show a disparity between the paraffin retention of 
tissue based upon histological types.  
 
I feel your audience will be interested and enlightened by these findings and the 
methodological approach taken. I hope that this paper will communicate this interesting 
research area directly to the biomedical Spectroscopists and wider audience that your journal 
has. I expect that this paper will be a driver for further research into sample preparation for 
spectral histopathology 
 
Please do not hesitate to get in touch if you have any questions or queries as I would relish 
any opportunity to discuss this research with you or your editorial board. 
 
Yours faithfully 
 
 
Dr Matthew J Baker 
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Dear Editorial Team, 
 
We would like to thank the reviewers for their time taken in reviewing the article. Please find 
my answers to specific points raised by each reviewer below, all changes are highlighted in the 
paper in red. 
 
Referee: 1 
Comments to the Author 
The authors use Raman microspectroscopy in order to detect the level of paraffin retained in thin 
sections from different types of cancerous tissues (mainly brain) after dewaxing. They compare the level 
of paraffin retained by tissues on 3 different substrates (CaF2, quartz, low-e glass) and by 4 different 
tissue types (normal brain, metastatic, primary brain tumour and glioblastoma). They make several 
claims: paraffin retention depends on the type of substrate and is lower on low-e slides; paraffin 
retention is higher in cancerous tissue than in normal tissue. They tentatively link this higher paraffin 
retention to cancerous tissue density. Some of these findings are new. Although not of primary 
importance, they can be useful to the bio-analytical community.  
Some results presented in this paper – the composition of the substrates – are clearly not new and could 
be removed.  
As advised, the section on composition of the substrates has been removed. 
Some results are not accurately reported – the level of paraffin retention in tissues – and should be 
significantly extended, and some data are lacking. More importantly, some findings cannot be 
substantiated by the provided data. 
We have attempted to address this general comment under the more specific points below. 
 
The paper is clearly written but a few points need to be clarified: 
-    There is a discrepancy in the number of samples in the Experimental and results sections (29 vs 31 
metastatic patients) 
This has been changed in the text. The number of metastatic patients is 29 
 
-    In Table 1, one of the patients is supposedly born in 2025; this is clearly an achievement in early 
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diagnosis ;-) 
 
Apologies, Table 1 has been revised 
 
Dewaxing Efficiency by Substrate Type 
Please note that a title for the first section of the results is lacking. 
 
The title “Dewaxing Efficiency by Substrate Type” has been added to the manuscript 
 
The findings that low-e slides retain less paraffin than CaF2 and quartz is new and may be of interest for 
the wider biospectroscopist community. However, the authors state that “the adherence to current 
clinical process will be advantageous”. It could be suggested that adherence to clinical practice requires 
the use of glass slides (that can not be used for infrared but can be used for Raman. The authors should 
describe why normal glass was not included in their study. Is it due to the incompatibility between glass 
and their laser frequency? If so this laser choice should be explained.  
When Raman spectroscopy is performed on Glass, there is a large fluorescent background within the 
region where the peaks of interest are contained. Low e slides, the same size as glass slides, were used 
due to their similarity, low cost and the ease with which they could be substituted for glass in clinical 
processes. The following has been added to the introduction: 
“Commercial glass microscope slides exhibit a very large fluorescent background under excitation in the 
near infra red, and are thus not suitable. Therefore, common spectroscopy substrates currently used 
include quartz, CaF2 and low-E microscope slides, the latter being relatively low cost.
28” 
Although paraffin adhered more to CaF2 and quartz than to low-e slides with the dewaxing protocol 
used in this study, it would be of great interest if the authors would discuss or investigate whether 
longer/more stringent dewaxing procedures would result in better dewaxing on these substrates. 
Especially since authors stated in the introduction that alternative dewaxing protocols (hexane) can be 
more efficient. 
The text has been modified to include “An important advantage in using spectroscopy for diagnosis is 
the short diagnostic window; therefore, a dewaxing solvent that requires a long processing time period is 
not an attractive option for this field of study” 
…. 
The SEM/EDX results obtained on quartz, low-e slides and CaF2 are clearly not new and should be 
removed. There is no knowledge gained in showing that quartz and glass are made of Si and O, and that 
CaF2 is made of Ca and F. The AFM experiments are relevant to the problem. 
 
The SEM/EDX results have been removed from the manuscript 
 
Spectral Histopathology: Dewaxing Efficiency by Tissue Types 
First, the reporting of this finding is clearly lacking as there is no numerical data, only 3 averaged 
spectra are provided, and readers are given no mean to estimate the variability of the paraffin signal 
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within each group. Quantitative data should be reported with standard deviations or other means to judge 
the variability of the data.  
A further Figure (Figure 8) has been added to the manuscript.  
 
The legend below has been added to the figure and manuscript 
 
“Figure 8.  The average intensity and standard deviation of three intense paraffin peaks at 1061, 1131 
and 1294 cm-1 for the three tissue types; Normal tissue (blue), Glioblastoma multiforme (red) and 
Metastatic brain cancer (green)” 
 
The manuscript has been changed to read 
 
“Figure 8 shows the average intensity and standard deviation of the intense paraffin peaks at 1061, 1131 
and 1294 cm-1. As can be seen, there is a trend to greater paraffin retention in normal to the cancerous 
states, metastatic tissue retaining the most paraffin, after the same processing procedures. Further 
imaging studies are planned to examine the impact of the substrate upon paraffin retention, as there 
seems to be an interplay of tissue dependence and substrate dependence where the paraffin clumps upon 
the substrate surface, as can be seen in Figure 5.” 
 
 
Second, only 2 types of brain cancer are compared with normal tissue in Figure 10 while 3 types of 
tumours (GBM, metastatic and primary) are described in the Experimental section. The results from 
primary brain tumours must be given.  
The reference to primary tumours has been removed from the experimental section for ease of 
understanding. The primary brain tumours (GBM) are already shown in the results. The primary 
tumours previously referred to in the experimental section are the original tumour sites of the metastatic 
brain tumours and hence were different tissue (i.e. breast) and were not suitable for the comparison of 
paraffin retention. 
 
Third, the protocol is not adapted to show a correlation between paraffin signal and pathological status 
because it doesn’t measure the paraffin signal accurately and because the spectra were recorded on CaF2 
windows which – as shown by the authors – are a cause of paraffin retention. The study should be made 
on low-e slides to minimise retention from the slide. The authors used either 100X or 60X immersion 
objectives and a 785nm laser, the laser spot size at sample must be in the micron range although no 
information is given in experimental section.  
The text has been modified in the section, Experimental: Raman spectroscopy instrumentation and 
analysis 
“Point spectra were acquired using a x 100 (Olympus MPlanN, NA = 0.9, spotsize ~1µm) objective and 
immersion point spectra were taken using a x 60 (Olympus LUMPlanFLN, NA = 1.0, spotsize ~ 1.5 µm) 
objective.” 
 
They report recording around 22 spectra per sample. This low sampling can not accurately measure the 
quantity of paraffin in sections of several square millimeters, even less so since some sample are highly 
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heterogeneous (Figure 1) and may accumulate different paraffin levels in different regions. To 
substantiate the claim of higher retention by cancerous tissues, it would require measuring the amount of 
paraffin retained in representative area of the sections maybe using an infrared imager to quickly collect 
images on several square millimeters.  
The aim was not to quantify the paraffin within several square millimetres of section, as the reviewer 
correctly states, and this would most likely require an FTIR equipped with an FPA. Rather, this study 
targeted cancerous areas of tissue and examined non-cancerous tissue from multiple patients and it was 
discovered that the paraffin retention is different between cancerous and non-cancerous tissue. 
In addition, the results presented by the authors in the first part of the paper suggest that the level of 
paraffin retention is a feature of the slide surface roughness that may vary locally on a window, may also 
vary on different CaF2 windows, and from batch to batch.  
The manuscript has been changed to read “The substrates had not been used for prior investigations and 
were fresh for this study. The measurements were taken from multiple slides and multiple places on 
each slide so batch to batch variability should not affect the trends in the data shown.” 
The level of paraffin may be higher in the metastatic tumor sample due to the simple fact that their 
architecture is different and that the dewaxing procedure is less efficient than in the other samples. This 
is not discussed.  
The reviewer is correct and indeed we had attempted to make this point in the discussion. For clarity, the 
text has been amended to read: 
“Abnormal tissue can be of very different morphology than normal tissue. A difference in tissue density 
could provide an explanation for the inconsistency of the dewaxing efficiency, and thus the variation of 
paraffin peak intensity between the normal brain and cancerous brain tissue spectra.” 
The tentative explanation given in the Discussion section fails to convince as extending findings on 
breast tumour to brain tumours appears arbitrary, and data linking brain tissue density to tumorous status 
are not provided. These results are thus clearly not substantiated and should be removed from the paper.  
We accept the reviewers point and as such the manuscript has been changed to provide a more relevant 
argument. 
“Berrtholdo  et al.  correlate increased choline signals from Magnetic Resonance Spectroscopy as a  
measure of malignancy in brain tumours due to  increased glial cell density as choline is a marker of 
cellular membrane turnover reflecting cellular proliferation38. Therefore, the disparity of wax retention 
between normal and cancerous tissue evident in figure 7 can be proposed to de due to local differences 
in tissue density. 
In the discussion it is stated that for breast tissue “state that the amount of fibro-glandular and adipose 
tissue is strongly related to the risk of developing cancer”. The proposed method for dewaxing 
eliminates all fat from tissues including myelin from axons and probably modifies protein through 
precipitation and hydrolysis, potentially destroying useful information for spectroscopic diagnosis. This 
should be discussed and the advantages of “computationally” dewaxing tissue section spectra as shown 
by the work of Sockalingum, Gobinet, Manfait and al. should be discussed. 
 
The following text has been added to the discussion 
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“The results indicate that tissue processing still remains an issue for Spectropathology, 
particularly using Raman spectroscopy. For clinical relevancy, however, and indeed acceptance of the 
techniques by the clinical community, it is important that the sample preparation and measurement 
protocols for Raman spectroscopic analyses are consistent with current clinical practice. Choice of 
substrate for routine clinical analyses may be dominated by economic considerations, thus favouring low 
E slides. Paraffin embedding facilitates tissue cutting, but also is commonly employed, worldwide, for 
archiving tissue samples. The availability of a wide range of pathologically characterized samples for 
study potentially enables extensive retrospective studies using spectroscopic and other techniques. The 
embedding process and wax itself can, however, contribute significantly to the spectroscopic signature 
of the tissue 40. An alternate method of “digital dewaxing” biological specimens to remove paraffin 
contributions of the spectrum has been proposed by Gobinet et al., recognising that chemical dewaxing 
methods are known to be inefficient for the complete removal of wax in tissue and can cause alterations 
to the samples. Their method of dewaxing consists of an estimation of the paraffin sources in the 
spectrum using Independent Component Analysis (ICA), followed by a Non-negatively Constrained 
Least Squares (NCLS) method to subtract the contributions. This enables removal of the paraffin signals 
to allow analysis of the underlying tissue spectrum 33. However, although “digital dewaxing” has been 
demonstrated41, it is also often important to compare spectroscopic profiling with parallel histological 
analyses, requiring chemical dewaxing of sections, a process which adds to the sample variability. The 
observation of variable dewaxing efficiencies depending on tissue pathology ads complexity to the 
challenge, perhaps requiring a combination of established clinical dewaxing protocols with 
computational procedures.” 
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Referee: 2 
Comments to the Author 
Dear Authors, 
The submission addresses very fundamental issues in vibrational spectroscopy. The work presented is 
succinct and to the point. Excluding minor typos and omissions, listed below, I recommend the text for 
publication. 
 
1) Pg. 8 - World Health Organization, name of the organization  
This has been changed in the manuscript and W, H and O has been capitalised 
 
2) Pg. 8 - haemotoxylin and eosin, name of chemicals  
This has been changed in the manuscript, h and e are now not capitalised 
 
3) Pg. 8 - HistoClear, trade name of chemical  
This has been changed in the manuscript H and C are now capitalised 
 
4) Pg. 9 - EM CCD, electron multiplying CCD  
This has been changed in the manuscript 
 
5) The formatting of company affiliation is not consistent throughout the text 
 
 
This has been changed in the manuscript 
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Referee: 3 
Comments to the Author 
In the context of spectral histopathology, this article studies by Raman spectroscopy the influence of the 
substrate choice and of the analyzed tissue type on the efficacy of chemical dewaxing. This work is 
innovative and addresses a problem that was never pointed out before. However, this article  leads to 
minor and major comments and questions. 
 
1) The title is not enough specific. The authors should precise that the study is realized using Raman 
spectroscopy. 
The title has been changed to read 
Effect of Substrate Choice and Tissue Type on Tissue Preparation for Spectral Histopathology by 
Raman Microspectroscopy 
 
2) The introduction is ambiguous because infrared and Raman spectroscopy are mixed throughout. 
Thus, I thought that the two techniques would be used in the rest of the paper. The authors thus should 
justify the construction of their introduction or should change their introduction in order to focus on 
Raman spectroscopy. 
A paragraph has been added to the introduction in answer to this comment. The text now reads 
“The contribution of paraffin peaks in vibrational spectra is apparent in both infrared and Raman 
spectroscopy. However, these peaks appear more prominently in the spectra of the latter technique; thus, 
Raman spectroscopy was used in this study to analyse the efficacies of current dewaxing techniques.” 
 
3) The ambiguity of the introduction is also illustrated by its first paragraph which focuses on prostate 
cancer. Thus, I thought that the study would be based on prostate tissues. Why not constructing this 
paragraph on brain cancer? 
A sentence has been added and the manuscript now reads “There have been many studies of different 
pathologies but the issues are well demonstrated by the example of prostate cancer.” 
 
4) In page 6 of the received manuscript, the sentences "O Faolain et al. suggest that the complete 
removal of paraffin from the tissue section is not possible to assess accurately with FTIR spectroscopy 
using the ~1462 cm-1 signal and should be performed using Raman spectroscopy. This was concluded 
following analysis of Raman and FTIR spectra obtained from identically deparaffinised tissue sections 
in which spectral peaks characteristic of paraffin wax were more clearly resolved in Raman spectra 
(strong sharp bands), compared with FTIR spectra" are almost entirely copied/pasted from a sentence of 
the reference [26] of Lyng et al. Authors should personalize these sentences.  
The manuscript has been changed to read 
“Ó Faoláin et al. indicate that Raman spectroscopy is much more sensitive to assess the incomplete 
removal of wax than FTIR” 
 
5) Furthermore, the authors refer to reference [26] of Lyng et al. for these sentences. However, these 
sentences summarize the work of Faolain et al. in the following article, which should be added in the 
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reference part of the paper: 
E.O. Faolain, M.B. Hunter, J.M. Byrne, P. Kelehan, M. McNamara, H.J. Byrne, F.M. Lyng, A study 
examining the effects of tissue processing on human tissue sections using vibrational spectroscopy, 
Vibrational Spectroscopy, 38, 121-127, 2005. 
The reference has been added 
 
6) Page 7, authors write that "CaF2 has been shown to be better for Raman measurements". Should they 
provide references proving this claim? 
The following reference has been added to support the comparison of substrates: 
" Collagen matrices as an improved model for in vitro study of live cells using Raman microspectroscopy", 
F. Bonnier, P. Knief, A. D. Meade, J. Dorney, K. Bhattacharya, F. M. Lyng and H. J. Byrne, 
Clinical and Biomedical Spectroscopy and Imaging II, edited by Nirmala Ramanujam, Jürgen Popp, 
Proc. of SPIE-OSA Biomedical Optics, SPIE Vol. 8087, 80870F·(2011) 
 
7) Are the sections for H&E staining and Raman acquisition directly adjacent? 
The manuscript has been changed to read “The tissue sections used from each sample were cut 
consecutively with one section used for Raman analysis and one for haematoxylin and eosin staining” 
 
8) Why didn't the author consider in their study glass substrate since it is classically used in clinical 
routine? 
When Raman spectroscopy is performed on Glass there is a large fluorescent background within the 
region where the peaks of interest are contained. Low e slides the same size as glass slides were used 
due to their similarity and the ease with which they could be substituted for glass in clinical processes. 
The text has been amended to read: 
“Commercial glass microscope slides exhibit a very large fluorescent background under excitation in the 
near infra red, and are thus not suitable. Therefore, common spectroscopy substrates currently used 
include quartz, CaF2 and low-E microscope slides, the latter being relatively low cost.” 
Note: This question was also raised by reviewer 1 and thus the amended text is highlighted in red 
 
9) In E.O. Faolain et al, Vibrational Spectroscopy, 38, 2005, normal parenchymal tissue from the 
placenta was chosen because it is an homogenous tissue. What are the arguments of the authors to 
explain their choice to analyze brain tissues? 
The authors use brain tissue as this work is part of a larger study on the use of spectral histopathology 
for the diagnosis and detection of brain tumours. 
 
10) In reference [25], E.O. Faolain et al showed that hexane is a more effective dewaxing agent than 
Histoclear. Thus, why did the authors prefer to use Histoclear?  
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HistoClear is the clinical standard and the authors used HistoClear in order to assess the current clinical 
practices and their use within the developing field of spectral histopathology. 
The text has been modified to clarify 
“An important advantage in using spectroscopy for diagnosis is the short diagnostic window; therefore, 
a dewaxing solvent that requires a long processing time period is not an attractive option for this field of 
study.” 
Note: This question was also raised by reviewer 1 and thus the amended text is highlighted in red 
 
11) In page 9, in the "Raman spectroscopy instrumentation and analysis" section, authors write 
"immersion point spectra". What does it mean and for which acquisitions was it used? 
The following text has been added to the manuscript 
Immersion spectroscopy was used for measurement of the tissue samples for spectral histopathology. 
Immersion Raman utilises an immersion lens which is in direct contact with a liquid that the sample 
under analysis is submerged in, such as deionised water used in this study. Bonnier et al. describe the 
use of immersion Raman spectroscopy and demonstrate its successful use for improving spectral 
quality34,35. 
 
12) The authors should precise the average number of Raman spectra acquired on each section. 
The manuscript has been changed to read 
“From each tissue section 20 spectra were acquired from different regions, depending upon the size of 
the tissue slice.” 
 
13) For normal tissue, on which structures did the authors make the acquisitions: white matter, gray 
matter, ...? These structures having different densities, have the authors analyzed the influence of the 
type of analyzed structure for the same section on the dewaxing procedure efficacy? The same questions 
are asked for the tumoral tissues. 
For normal tissue, an approach to the spectral acqusition was taken as it would be in the clinic. i.e all 
and any normal tissue was analysed. The trends seen therefore are across all the sturcture of normal 
brain analysed as no particular area was targeted. As for tumoral sections, these are all cancerous areas 
and were not analysed according to the origin of the structure, again mimicking clinical practice. 
The trends seen are therefore general trends linked to the retentation by the vastly different tissue types 
of normal, high grade cancer and metastatic.  
The following text has been added in the experimtnal section 
For all tissue samples, sample analysis by spectral acquisition was carried out as it would be in the 
clinic. i.e all and any normal tissue was analysed, and no particular area was targeted (eg white/grey 
matter). Similarly, for tumoral sections, all cancerous areas were analysed irrespective of  the origin of 
the structure, again mimicking clinical practice. 
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14) In page 10, in the "Data pre-processing" section, the authors should provide a reference or explain 
the method used to subtract the background. 
The manuscript has been changed to read 
“background subtraction was performed through the application of a fifth order polynomial and 
smoothed using 7 point smoothing” 
 
15) In page 10, in the "Data pre-processing" section, I do not understand the sentence "using the 
cytospec code written by Dr A Henderson" since CytoSpec has been developed by Peter Lasch. Who is 
A Henderson and what is his link with CytoSpec and this article? 
The manuscript has been changed to read “using in-house written code” 
 
16) In page 11, in the "Results and discussion" section, what is the aim of the microscopic observation 
of the substrate surface? What information is supplied by right panel images of figures 3, 4 and 5? Are 
these figures necessary since they are not commented in the results? 
These figures have been removed on recommendation of Reviewer 1. 
 
17) In page 13, in the "Results and discussion" section, the authors should compare their results 
(complete dewaxing on low-E MirrIR slide) to those obtained by Faolain et al, Vibrational 
Spectroscopy, 38, 2005 (incomplete dewaxing on MirrIR slide).  
The study by O Faoláin et al., was conducted under somewhat different circumstances (dewaxing 
protocol, tissue type). Nevertheless a comment has been added to the Results and discussion. 
 
“Indeed, it should be noted that, whereas in this study complete removal of wax was observed for tissue 
samples on low-E slides, O’ Faoláin et al. 39 reported incomplete was removal from normal parenchymal 
tissue from the placenta, dewaxed using a xylene based protocol also measured in low-E slides.” 
 
18) The subsection title "Spectral histopathology: Dewaxing efficiency by tissue types" is useless since 
no such subsection title was provided for the first part of the "Results and discussion" section. 
A title has been added to the first part of the section 
 
19) Compared to the first part of the "Results and discussion" section, the second part concerning the 
study of the dewaxing efficiency by tissue types is very light. It mainly consist of the observation that 
normal tissues are better dewaxed than tumoral ones. Isn't it possible to demonstrate that tissue density is 
really responsible of this effect? What to conclude from this part of the study? 
The discussion has been added to with reference to the previous studies on parenchymal tissue from the 
placenta as well as further evidence of higher densities in brain tumours, allowing a stronger statement 
on dependence of dewaxing efficacy on tissue density. 
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Berrtholdo  et al.  correlate increased choline signals from Magnetic Resonance Spectroscopy as a  
measure of malignancy in brain tumours due to  increased glial cell density as choline is a marker of 
cellular membrane turnover reflecting cellular proliferation38. Therefore, the disparity of wax retention 
between normal and cancerous tissue evident in figure 7 can be proposed to de due to local differences 
in tissue density. 
Note: This question was also raised by reviewer 1 and thus the amended text is highlighted in red 
 
 
20) On the one hand, the low-E MirrIR slide induces a perfect dewaxing of samples. On the other hand, 
CaF2 leads to incomplete dewaxing. In function of the type of tissue, the paraffin residue is variable, and 
thus CaF2 induces more discriminative information between different types of tissues thanks to paraffin 
residue. What is thus the position of the authors concerning the slide to choose for Raman analysis of 
FFPP samples?  
A further paragraph has been added to the Discussion section 
 
“The results indicate that tissue processing still remains an issue for Spectropathology, 
particularly using Raman spectroscopy. For clinical relevancy, however, and indeed acceptance of the 
techniques by the clinical community, it is important that the sample preparation and measurement 
protocols for Raman spectroscopic analyses are consistent with current clinical practice. Choice of 
substrate for routine clinical analyses may be dominated by economic considerations, thus favouring low 
E slides. Paraffin embedding facilitates tissue cutting, but also is commonly employed, worldwide, for 
archiving tissue samples. The availability of a wide range of pathologically characterized samples for 
study potentially enables extensive retrospective studies using spectroscopic and other techniques. The 
embedding process and wax itself can, however, contribute significantly to the spectroscopic signature 
of the tissue 40. An alternate method of “digital dewaxing” biological specimens to remove paraffin 
contributions of the spectrum has been proposed by Gobinet et al., recognising that chemical dewaxing 
methods are known to be inefficient for the complete removal of wax in tissue and can cause alterations 
to the samples. Their method of dewaxing consists of an estimation of the paraffin sources in the 
spectrum using Independent Component Analysis (ICA), followed by a Non-negatively Constrained 
Least Squares (NCLS) method to subtract the contributions. This enables removal of the paraffin signals 
to allow analysis of the underlying tissue spectrum 33. However, although “digital dewaxing” has been 
demonstrated41, it is also often important to compare spectroscopic profiling with parallel histological 
analyses, requiring chemical dewaxing of sections, a process which adds to the sample variability. The 
observation of variable dewaxing efficiencies depending on tissue pathology ads complexity to the 
challenge, perhaps requiring a combination of established clinical dewaxing protocols with 
computational procedures.” 
 
This section has also been added in response to a comment by Reviewer 1 
 
21) Page 19, the authors should write "Figure 2" instead of "Figure 1" 
Figure references have been corrected within the manuscript 
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22) Figures 3, 4 and 5 should be grouped together. 
These figures have been removed from the manuscript 
 
23) For figure 6, the averaged spectrum of low-E Mirr acquisitions is computed from 210 spectra, while 
around 450 are used for CaF2 and Spectrosil acquisitions. Why this huge difference? 
The spectra acquired are part of a larger study and as such there are different numbers of spectra for 
each substrate 
 
24) For figure 7, the averaged spectrum acquired on low-E Mirr shows no paraffin spectral contribution. 
This spectrum is thus characteristic of low-E Mirr. Why is this spectrum different from the reference 
spectrum of low-E Mirr presented on figure 2? 
Upon futher inspection, the bacground has been standardised acrosse the images 
 
25) The authors should provide a scale bar for images provided on figures 1 and 8. 
Scale bars have been added to these figures 
 
26) To compare the spectra of figure 10 and to make conclusions, averaged spectra +/- standard 
deviation should be plotted. 
A further Figure (Figure 8) has been added to the manuscript.  
 
The legend below has been addedd to the figure and manuscript 
 
“Figure 8.  The average intensity and standard deviation of three intense paraffin peaks at 1061, 1131 
and 1294 cm-1 for the three tissue types; Normal tissue (blue), Glioblastoma multiforme (red) and 
Metastatic brain cancer (green)” 
 
The manuscript has been changed to read 
 
“Figure 8 shows the average intensity and standard deviation of the intense paraffin peaks at 
1061, 1131 and 1294 cm-1. As can be seen, there is a trend to greater paraffin retention in normal to the 
cancerous states, metastatic tissue retaining the most paraffin, after the same processing procedures. 
Further imaging studies are planned to examine the impact of the substrate upon paraffin retention, as 
there seems to be an interplay of tissue dependence and substrate dependence where the paraffin clumps 
upon the substrate surface, as can be seen in Figure 5.” 
 
This section has also been added in response to a comment by Reviewer 1 
 
27) In table 1, one patient was born in 2029 and another one in 2025. 
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This has been modified in the revised manuscript 
 
 
Yours faithfully 
 
 
Dr Matthew J Baker 
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Abstract 
 
 Raman spectroscopy is a non-destructive, non-invasive, rapid and economical 
technique which has the potential to be an excellent method for the diagnosis of cancer and 
understanding disease progression through retrospective studies of archived tissue samples. 
Historically, biobanks are generally comprised of formalin fixed paraffin preserved tissue and 
as a result these specimens are often used in spectroscopic research. Tissue in this state has to 
be dewaxed prior to Raman analysis to reduce paraffin contributions in the spectra. However, 
although the procedures are derived from histopathological clinical practice, the efficacy of 
the dewaxing procedures that are currently employed is questionable. Ineffective removal of 
paraffin results in corruption of the spectra and previous experiments have shown that the 
efficacy can depend on the dewaxing medium and processing time. The aim of this study was 
to investigate the influence of commonly used spectroscopic substrates (CaF2, Spectrosil 
quartz and low-E slides) and the influence of different histological tissue types (normal, 
cancerous and metastatic) on tissue preparation and to assess their use for spectral 
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histopathology. Results show that CaF2 followed by Spectrosil contribute the least to the 
spectral background. However, both substrates retain paraffin after dewaxing. Low-E 
substrates, which exhibit the most intense spectral background, do not retain wax and 
resulting spectra are not affected by paraffin peaks. We also show a disparity in paraffin 
retention depending upon the histological identity of the tissue with abnormal tissue retaining 
more paraffin than normal. 
 
Keywords Cancer, Diagnosis, Raman, Substrate, Histopathology, Vibrational Spectroscopy 
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Introduction 
 
The primary requirement for successful treatment of any disease is early detection. 
Cancer incidence rates have continued to rise 1, although survival rates for cancer are 
increased with early diagnosis. Current methods used in cancer diagnosis focus on changes in 
architecture of tissue, cells or internal constituents and the identification of protein 
expression. Research performed into identification of protein expression in blood has 
produced single biomarkers for specific cancers that have become misleading. There have 
been many studies of different pathologies but the issues are well demonstrated by the 
example of prostate cancer. The Prostate Specific Antigen (PSA) test is used to indicate 
prostate cancer (CaP). However, approximately 40 % of organ confined CaP show no 
elevation of PSA 2 and many other benign conditions can show increased PSA serum, thus 
producing false positives in screening. Hoffman et al. suggest that CaP screening would 
benefit from improved biomarkers, which more readily identify clinically important cancers 
3. As cancer is a heterogeneous disease, a set of markers or a whole sample profile will 
provide significantly more diagnostic information than any one marker 4. After initial 
indication of cancer, diagnosis is confirmed by biopsy and assessment of tissue architecture. 
The biopsy is assessed based upon a subjective measurement. For CaP this is called the 
Gleason grading system and in a study of 390 patients identical grades were assigned to only 
29.2% of the tumours by different histopathologists 5. Pathological discrepancies are reported 
to occur in up to 43% of specimens assessed via histopathology 6. The accurate and rapid 
diagnosis of disease allows early intervention of appropriate treatment, thus increasing life 
expectancy and reducing healthcare costs 7. Therefore, there is a requirement for non-
subjective techniques that can rapidly and accurately identify disease. 
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 Spectroscopic techniques, such as Raman and Infrared (IR), are excellent methods for 
the analysis of a wide range of materials. They are non-destructive, rapid, cost-effective and 
simple to operate. The inelastic (Raman) scattered light from molecules under irradiation is 
wavelength-shifted with respect to the incident light by molecular vibrations. The Raman 
spectrum is complementary to that of IR which represents the absorption of incident light at 
the resonant frequency of the bond or group, exciting vibrational modes. Different 
biomolecules exhibit responses to different wavelengths of light; the resultant spectrum can 
be thought of as a ‘fingerprint’ of the sample. Spectroscopic analysis allows the objective 
classification of biological material on a molecular level8. Previous studies have 
demonstrated the use of spectroscopy (imaging and point spectra) to analyse gastrointestinal 
(GI) tract 9, 10, lung 11, 12, cervix 13, 14, brain 15, 16,breast 17, 18, prostate 19-21 and lymph node 
cancers 22, 23. Initial work has focused on differentiating between normal tissue and advanced 
cancers. Technological development is enabling diagnosis at progressively earlier stages and 
potential to do so in vivo 24. The aim of these studies is to develop spectral histopathology 
based upon objective chemical information. 
 
In order to develop spectral histopathology, a database of tissue spectra is required to 
enable spectral disease identification. The ideal situation would be to build this database 
using fresh or frozen tissue sections. However, historically, biobanks have been built using 
Formalin Fixed Paraffin Preserved Tissue (FFPP) sections, which are fixed using formalin 
and impregnated with paraffin wax to preserve the tissue for future analysis and provide 
support to aid microtomy for sectioning the tissue block to enable microscopic examination. 
Prior to histological and/or spectral analysis, the tissue sections generally undergo a 
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dewaxing process, to allow histological staining of the tissue for pathological examination 
and to reduce paraffin contributions in vibrational spectra, consequently, returning the tissue 
to as much of an in vivo state as possible 25. 
 
Ó Faoláin et al. investigated the efficacy of dewaxing procedures on formalin fixed, 
paraffin preserved (FFPP) cervical tissue on glass slides 25. They reported that dewaxing 
procedures employing, the commonly used xylene and HistoClear solvents do not completely 
remove all of the paraffin wax. Although, they found hexane to be a much more efficient 
dewaxing agent, it requires 18 hours of tissue submersion and is not clinically used for 
dewaxing procedures 25. An important advantage in using spectroscopy for diagnosis is the 
short diagnostic window; therefore, a dewaxing solvent that requires a long processing time 
period is not an attractive option for this field of study. Ó Faoláin et al. indicate that Raman 
spectroscopy is much more sensitive to assess the incomplete removal of wax than FTIR. 
This was concluded following analysis of Raman and FTIR spectra obtained from identically 
deparaffinised tissue sections in which spectral peaks characteristic of paraffin wax were 
more clearly resolved in Raman spectra (strong sharp bands), compared with FTIR spectra 26. 
 
The contribution of paraffin peaks in vibrational spectra is apparent in both infrared 
and Raman spectroscopy. However, these peaks appear more prominently in the spectra of 
the latter technique; thus, Raman spectroscopy was used in this study to analyse the efficacies 
of current dewaxing techniques.  
 
Substrates are needed in spectral histopathology to support the samples during 
analysis. Samples are often relatively thin allowing incident light the opportunity of 
interacting with the substrate below. This interaction has an effect on the spectral 
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background; thus, the correct choice of substrate for spectroscopic analysis is essential for 
reducing this background and optimising the quality of the spectral data 27. Commercial glass 
microscope slides exhibit a very large fluorescent background under excitation in the near 
infrared, and are thus not suitable. Therefore, common spectroscopy substrates currently used 
include quartz, CaF2 and low-E microscope slides, the latter being relatively low cost.
28 
 
Recently, the choice of substrate has been a hot topic within the spectral 
histopathology field, as spectral artefacts have been identified in FTIR transflection analysis 
using highly reflective low-E slides29,30. However, when analysing tissue, a 2nd derivative 
spectrum minimises these contributions allowing for spectral histopathological diagnosis31.  
Both quartz and CaF2 are transparent over a large range of the mid-IR and are therefore 
suitable for transmission measurements, although CaF2 has been shown to be better for 
Raman measurements, and so is an obvious choice for use of both complementary 
techniques. The choice of substrate is also important if spectral diagnoses are going to be 
effective in the clinical setting, substrates that can easily fit into current methodologies (due 
to size, solubility etc.) are advantageous and also cost needs to be minimised to ensure 
efficient health services. 
 
Vibrational spectroscopy has the potential to revolutionise the clinical environment, 
allowing for increased efficiency within the diagnostic regime with corresponding decreases 
in mortality, morbidity and economic impact upon the health services 32.  In order to achieve 
this potential, research needs to be performed to understand the impact of sample preparation 
upon the vibrational spectrum. We present, for the first time, a study of the effect and 
efficiency of the dewaxing process, using a clinical standard HistoClear procedure, by 
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substrate and tissue type utilising Raman spectroscopy in order to develop the basis of 
standard approaches for spectral histopathology. 
 
Experimental 
 
Study participants 
 
Tissue sections cut, by microtomy, at both 4 µm onto glass microscope slides and 10 
µm onto spectroscopic substrates: low-E MirrIR slides (Kevley Technologies, Chesterland, 
OH, 44026, USA), Spectrosil quartz (Starna Scientific) and calcium fluoride (CaF2) 
(Crystran), were obtained from formalin fixed paraffin preserved (FFPP) tissue blocks from 
the Brain Tumour North West (BTNW) bio-bank under ethical approval (BTNW/WRTB 
13_01). The substrates had not been used for prior investigations and were fresh for this 
study. The measurements were taken from multiple slides and multiple places on each slide so batch 
to batch variability should not affect the trends in the data shown. The tissue sections used from 
each sample were cut consecutively with one section used for Raman analysis and one for 
haematoxylin and eosin staining. Patient data consisted of histological information, patient 
gender and date of birth, origin of metastasis/histological subtype. A total of 48 tissue 
specimens were obtained from 41 different patients. Tissue consisted of normal brain samples 
(n=7), glioblastoma multiforme (GBM) brain samples WHO (World Health Organisation) 
grade IV (n=5) and metastatic brain samples (n=29). Table 1 displays further information 
about the tissue specimens.  
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 Dewaxing and Haematoxylin and Eosin staining of tissue 
 
Tissue sections on the microscope slides needed to undergo staining with 
haematoxylin and eosin (H&E) for parallel histological examination. The sections were de-
waxed before staining, carried out by: 2 x 5 minute baths of HistoClear followed by 2 x 5 
minute baths of ethanol. The tissue sections were washed in distilled water for 5 minutes after 
de-waxing, prior to H&E staining. Sections were bathed in haematoxylin for 5 minutes and 
then washed in warm tap water to allow the nuclei to turn blue. The sections were then 
covered in eosin for 4 minutes and rinsed with distilled water. Finally, the tissue sections 
were dehydrated in 2 x 5 minute baths of ethanol and cleared in 2 x 5 minute baths of 
histoclear, and then protected and preserved through the application of HistoMount and a 
coverslip. The sections were then microscopically examined in order to identify the 
metastatic sites present in the tissue.   
 
Figure 1 shows the microscopic images of the H & E stained tissue samples at x 100 
magnification. It can be observed that normal brain, metastatic and GBM brain tissue 
architecturally differ from one another and between the metastatic types. 
 
Tissue section preparation for Raman spectroscopic analysis 
 
 The tissue sections on Raman substrates needed to be de-waxed prior to Raman 
analysis in order to reduce the paraffin peak contributions in the spectra. The de-waxing 
procedure consisted of 3 x 5 minute baths of HistoClear followed by 3 x 5 minute baths of 
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ethanol. The sections were left to air dry for 30 minutes, placed in a Petri dish and stored in a 
desiccator until spectroscopic analysis. 
 
  
Raman spectroscopy instrumentation and analysis 
Spectroscopic measurements were carried out using a Horiba Jobin-Yvon LabRAM HR800 
spectrometer. An air cooled CLDS point mode diode 785 nm laser with a single edge filter  
(cut off to 100 cm-1) and an output power of 300 mW was used to acquire spectra; which was 
used with a grating of 300 gr/mm and blazed at 1000 nm. Point spectra were acquired using a 
x 100 (Olympus MPlanN, NA = 0.9, spotsize ~1µm) objective and immersion point spectra 
were taken using a x 60 (Olympus LUMPlanFLN, NA = 1.0, spotsize ~ 1.5µm). Immersion 
spectroscopy was used for measurement of the tissue samples for spectral histopathology. 
Immersion Raman utilises an immersion lens which is in direct contact with a liquid that the 
sample under analysis is submerged in, such as deionised water used in this study. Bonnier et 
al. describe the use of immersion Raman spectroscopy and demonstrate its successful use for 
improving spectral quality34,35. 
 
The confocal hole was set at 100 µm for 785 nm spectral collections. The detector used was 
an Andor charged coupled device (CCD). A video camera within the Raman system was used 
to take images of the specimens. The instrumentation was calibrated before operation to 
silicon at the spectral line of 520.8 cm-1. Spectra were acquired using the 785 nm laser at 
100% exposure for 30 s and accumulated twice. From each tissue section 20 spectra were 
acquired from different regions, depending upon the size of the tissue slice. 
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For all tissue samples, sample analysis by spectral acquisition was carried out as it would be 
in the clinic. i.e all and any normal tissue was analysed, and no particular area was targeted 
(eg white/grey matter). Similarly, for tumoral sections, all cancerous areas were analysed 
irrespective of the origin of the structure, again mimicking clinical practice. 
 
Data pre-processing 
 
Pre-processing was carried out on the raw data using LabSpec 6 spectroscopy 
software suite (HORIBA Scientific, Japan) and MATLAB version 7.11.0 (R2010b) (The 
MathWorks, Inc., USA) using in-house written software. Pre-processing methods were kept 
to a minimum to enable better reproducibility; background subtracted was performed through 
the application of a fifth order polynomial and smoothed using 7 point smoothing (Labspec 6) 
and vector normalised (Matlab) using in-house written code.  
 
Atomic force microscope (AFM) 
 The atomic force microscope (AFM) model that was used to image the samples for 
surface morphology for this study is the MFP-3D-BIO (Asylum Research, USA), with 
Olympus silicon AC160 cantilevers. The tips were 160 nm long with resonant frequencies 
typical of 320 kHz. A/C mode was employed for operation to reduce tip/sample. 
 
Results and Discussion 
 
Dewaxing efficiency of spectroscopic substrates     
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Raman spectra of the three substrates: low-E, Spectrosil and CaF2, were acquired 
under identical conditions to generate spectral ‘fingerprints’ of the substrates, shown in 
Figure 2, and thus ascertain the impact of their contribution to the spectral background.  
 
It can be observed that low-E has the highest intensity baseline and CaF2 has the 
lowest intensity baseline of the three substrates; indicating that spectra taken from samples on 
CaF2 are less affected by substrate background than either low-E or Spectrosil and should 
display background peaks of lower intensities. 
 
The spectra of dewaxed tissue samples on the three different substrates were 
compared to further investigate the level of influence substrate type has on the outcome of 
spectra. Figure 3 displays average spectra of dewaxed tissue on the three substrates and a 
paraffin spectrum for comparison 
 
A paraffin spectrum displays significant peaks at 888 cm-1, 1061 cm-1, 1131 cm-1, 
1171 cm-1, 1294 cm-1, 1417 cm-1, 1440 cm-1, 1462 cm-1 (Figure 3), which can be assigned to 
C-C stretching and CH2 and CH3 deformations within the molecule 
25. It can be seen from 
Figure 3 that the spectra from the dewaxed tissue samples on Spectrosil and CaF2 exhibit 
residual paraffin peaks. However, dewaxed tissue spectra on low-E do not display visible 
paraffin peaks.  
 
In order to further investigate any substrate effect on the dewaxing process, paraffin 
wax was analysed on the substrates without the presence of tissue specimens. Paraffin wax 
was cut at 10 µm sections and mounted onto the three different substrates. The substrates 
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were then dewaxed by the same method as the FFPP tissue samples and analysed; Figure 4 
displays the resulting spectra. Residual wax, still present on both the Spectrosil and CaF2 
substrate, could be seen visually both macroscopically and microscopically, shown in Figure 
5, and its presence was confirmed by paraffin peak contributions in their spectra. The low-E 
substrate did not retain any visual paraffin wax and no paraffin peaks were present in the 10 
spectra taken from the substrate. This shows, for the first time, a substrate effect that occurs 
during the dewaxing process inferring that as a result of surface chemistry or morphology, 
low-E slides facilitate the removal of wax more readily than CaF2 and Spectrosil. From 
Raman analysis and visual inspection, it is clear that, using the same dewaxing protocol, the 
low-E substrate is fully dewaxed, yet the CaF2 and Spectrosil substrates retain paraffin wax.  
 
Atomic force microscopy (AFM) was utilised to assess the three substrates’ surface 
roughness. The AFM images of the three substrates are displayed in Figure 6, showing the 
surface morphology at a nanoscopic level. The low-E substrate was observed to have a far 
smoother surface than either CaF2 or Spectrosil with an average surface roughness of 1.10 nm 
compared to 4.76 nm and 3.88 nm respectively. Low-E slides are coated with metal oxide36; 
this could explain why their surface is far smoother than the other substrates which are only 
polished.    
 
The clinical application of spectral histopathology is the ultimate aim of this field. As 
such, the adherence to current clinical process will be advantageous. The use of Low-E slides 
holds a number of advantages for this, such as low cost, their microscope slide size and 
robustness when compared to other substrates. Although substrate spectral background is 
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higher, all tissue spectral peaks that are detected when using other substrates are present in 
the spectrum. 
 
Spectral Histopathology: Dewaxing Efficiency by Tissue Types 
Although low-E substrates clearly perform better in terms of wax removal from the 
tissue sections using routine clinical protocols, CaF2 is commonly used in Raman 
spectroscopic studies due to its low contribution to the spectral background (Figure 2). It is of 
interest to investigate whether the tissue type mounted on these substrates also contributes to 
the residual signals. The vector normalised mean Raman spectra of dewaxed sections of 
normal (157 spectra from 7 patients), metastatic (668 spectra from 29 patients) and GBM 
(127 spectra from 5 patients) brain tissue on CaF2 substrates are displayed in Figure 7. It can 
be observed from the averaged spectrum of normal tissue that the paraffin peaks (asterisked 
peaks) are not fully removed by the dewaxing process, but notably the characteristic features 
are of a much lower intensity than those in the spectra of metastatic and GBM tissue Figure 8 
shows the average intensity and standard deviation of the intense paraffin peaks at 1061, 
1131 and 1294 cm-1. As can be seen, there is a trend to greater paraffin retention in normal to 
the cancerous states, metastatic tissue retaining the most paraffin, after the same processing 
procedures. Further imaging studies are planned to examine the impact of the substrate upon 
paraffin retention, as there seems to be an interplay of tissue dependence and substrate 
dependence where the paraffin clumps upon the substrate surface, as can be seen in Figure 5. 
 
Abnormal tissue can be of very different morphology than normal tissue. A difference 
in tissue density could provide an explanation for the inconsistency of the dewaxing 
efficiency, and thus the variation of paraffin peak intensity between the normal brain and 
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cancerous brain tissue spectra. For breast cancer Li et al. state that the amount of fibro-
glandular and adipose tissue is strongly related to the risk of developing cancer. They explain 
that, although no direct evidence has been found to link dense mammographic tissue with the 
increased chance of developing breast cancer, the correlations observed have encouraged the 
use of tissue density for breast cancer monitoring. They go on to support the observations of 
this correlation through their findings that the mammograms of cancerous breast tissue are far 
denser than those of normal breast tissue 37. Berrtholdo  et al. correlate increased choline 
signals from Magnetic Resonance Spectroscopy as a  measure of malignancy in brain 
tumours  due to increased glial cell density as choline is a marker of cellular membrane 
turnover reflecting cellular proliferation38. Indeed, it should be noted that, whereas in this 
study complete removal of wax was observed for tissue samples on low-E slides, O’ Faoláin 
et al. 39  reported incomplete was removal from normal parenchymal tissue from the placenta, 
dewaxed using a xylene based protocol also measured in low-E slides. 
 
The results indicate that tissue processing still remains an issue for Spectropathology, 
particularly using Raman spectroscopy. For clinical relevancy, however, and indeed 
acceptance of the techniques by the clinical community, it is important that the sample 
preparation and measurement protocols for Raman spectroscopic analyses are consistent with 
current clinical practice. Choice of substrate for routine clinical analyses may be dominated 
by economic considerations, thus favouring low E slides. Paraffin embedding facilitates 
tissue cutting, but also is commonly employed, worldwide, for archiving tissue samples. The 
availability of a wide range of pathologically characterized samples for study potentially 
enables extensive retrospective studies using spectroscopic and other techniques. The 
embedding process and wax itself can, however, contribute significantly to the spectroscopic 
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signature of the tissue 40. An alternate method of “digital dewaxing” biological specimens to 
remove paraffin contributions of the spectrum has been proposed by Gobinet et al., 
recognising that chemical dewaxing methods are known to be inefficient for the complete 
removal of wax in tissue and can cause alterations to the samples. Their method of dewaxing 
consists of an estimation of the paraffin sources in the spectrum using Independent 
Component Analysis (ICA), followed by a Non-negatively Constrained Least Squares 
(NCLS) method to subtract the contributions. This enables removal of the paraffin signals to 
allow analysis of the underlying tissue spectrum 33. However, although “digital dewaxing” 
has been demonstrated41, it is also often important to compare spectroscopic profiling with 
parallel histological analyses, requiring chemical dewaxing of sections, a process which adds 
to the sample variability. The observation of variable dewaxing efficiencies depending on 
tissue pathology ads complexity to the challenge, perhaps requiring a combination of 
established clinical dewaxing protocols with computational procedures. 
 
Conclusion 
This study shows the influence that Raman substrates have on resulting spectra from 
Raman analysis. Spectral backgrounds of the substrates show that the baseline of low-E is the 
highest and CaF2 the lowest of the three substrates. It has been established through 
observation and investigation that CaF2 and Spectrosil substrates retain paraffin wax after the 
dewaxing procedure is carried out whereas low-E does not. This is attributed to the difference 
in surface roughness and chemistry between substrates. AFM demonstrated that low-E 
substrates are far smoother than either CaF2 or Spectrosil substrates with average roughness 
of 1.10 nm compared to 4.76 nm and 3.88 nm respectively. 
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 This study has also observed the difference between the dewaxing efficiency between 
normal brain and cancerous brain tissue. This has been attributed to a change in density 
between normal and cancerous, which causes the denser cancerous tissue to retain wax better 
than the, less dense, normal tissue. It is important to note therefore that tissue processing 
procedures for spectral histopathology of normal tissue may not be optimised for abnormal 
regions. 
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List of Tables and Figures 
Table 1 Patient details with histological subtype and metastatic origin.    
Figure 1 Microscopic images of H&E stained tissue samples of normal brain, metastatic (from oesophagus and 
stomach, breast, colon/rectum, lung and melanoma as labelled above) and GBM brain WHO grade IV (x 100). 
Scale bar represents 50 microns. 
Figure 3 Averaged spectra of 458 CaF2 acquisitions, 210 low-E acquisitions and 465 Spectrosil acquisitions 
from all tissue specimens and a background-subtracted spectrum of paraffin wax. The tissue spectra have been 
vector normalised and offset for visual clarity. The asterisks above the peaks correspond to the paraffin 
contributions.    
Figure 4 Vector normalised, background corrected spectra of substrates after dewaxing from: 1 CaF2 
acquisition, 1 Spectrosil acquisition and 10 averaged low-E acquisitions. The spectrum of paraffin wax is 
included as a reference. The spectra have been appropriately scaled and offset for visual clarity.  
 Figure 5 Microscopic Raman images at x 10 of the substrate surfaces after dewaxing. Wax residuals can be 
observed on the CaF2 and Spectrosil substrates. Scale bars represent 0.5 mm. 
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Figure 6 AFM images of Spectrosil, CaF2 and Low-E substrates. 
 
Figure 7 Averaged immersion spectra of 127 GBM acquisitions, 668 metastatic acquisitions and 157 normal 
brain acquisitions. Normal tissue spectrum is shown with its standard deviation in red (top), GBM tissue 
spectrum is shown with its standard deviation in green (middle), and metastatic tissue spectrum is shown with 
its standard deviation in blue (bottom). Spectra have been vector normalised, the backgrounds have been 
corrected using a 5th order polynomial fit and subtraction and 7 points of smoothing. The asterisks correspond 
to paraffin peaks from residual wax in the tissue. 
Figure 8  The average intensity and standard deviation of three intense paraffin peaks at 1061, 1131 
and 1294 cm-1 for the three tissue types; Normal tissue (blue), Glioblastoma multiforme (red) and 
Metastatic brain cancer (green) 
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Table 1 Patient details with histological subtype and metastatic origin.    
 
BTNW no. Gender DOB Origin of Metastasis/histological 
subtype 
119 F 26/06/1963 Breast  
707 F 07/08/1945 Breast 
756 F 15/03/1957 Breast 
888 M 25/11/1948 Colon/rectum 
985 M 05/02/1933 Melanoma  
988 M 30/12/1949 Oesophagus & stomach 
1001 F 20/12/1944 Lung 
690 / 1012 F 25/10/1960 Breast  
1004 F 03/09/1956 Breast  
998 / 1010 M 25/07/1946 Colon 
1020 F 05/06/1948 Breast 
2 F 28/10/1937 GBM 
3 F 22/09/1981 GBM 
4 M 08/12/1942 GBM 
5 F 29/10/1958 GBM 
7 M 14/04/1939 Normal Brain 
10 F 13/06/1929 GBM 
78 F 24/09/1955 Lung 
106 F 14/02/1965 Normal Brain 
132 F 24/06/1943 Normal Brain 
136 F 25/09/1956 Normal Brain 
137 M 26/04/1944 Colon/rectum  
164 M 10/04/1954 Oesophagus & stomach 
184 F 21/11/1948 Lung 
215 M 21/01/1973 Lung  
274 M 12/07/1940 Colon/rectum 
295 F 12/06/1936 Lung 
358 M 08/05/1935 Melanoma 
409 F 08/08/1925 Colon/rectum 
444 M 30/01/1978 Normal Brain 
509 M 11/02/1930 Melanoma 
517 F 05/06/1955 Lung 
521 M 18/01/1949 Oesophagus & stomach 
562 F 12/03/1953 Lung 
567 F 09/04/1947 Melanoma 
668 F 30/08/1943 Colon/rectum 
678 F 13/11/1961 Normal Brain 
688 F 15/06/1965 Melanoma  
694 M 18/09/1951 Lung 
721 F 04/01/1976 Oesophagus & stomach 
772 M 21/09/1972 Normal Brain 
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Figure 1 Microscopic images of H&E stained tissue samples of normal brain, metastatic (from oesophagus and 
stomach, breast, colon/rectum, lung and melanoma as labelled above) and GBM brain WHO grade IV (x 100). 
Scale bar represents 50 microns. 
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Figure 2 Raw spectra of the substrate backgrounds: CaF2, low-E and Spectrosil. 
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Figure 3 Averaged spectra of 458 CaF2 acquisitions, 210 low-E acquisitions and 465 Spectrosil acquisitions 
from all tissue specimens and a background-subtracted spectrum of paraffin wax. The tissue spectra have been 
vector normalised and offset for visual clarity. The asterisks above the peaks correspond to the paraffin 
contributions.    
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 Figure 4 Vector normalised, background corrected spectra of substrates after dewaxing from: 1 CaF2 
acquisition, 1 Spectrosil acquisition and 10 averaged low-E acquisitions. The spectrum of paraffin wax is 
included as a reference. The spectra have been appropriately scaled and offset for visual clarity.  
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Figure 5 Microscopic Raman images at x 10 of the substrate surfaces after dewaxing. Wax residuals can be 
observed on the CaF2 and Spectrosil substrates. Scale bars represent 0.5 mm. 
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Figure 6 AFM images of Spectrosil, CaF2 and Low-E substrates. 
	  
Average	  surface	  roughness	  =	  3.88	  nm 
Average	  surface	  roughness	  =	  4.76	  nm 
Average	  surface	  roughness	  =	  1.10	  nm 
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Figure 7 Averaged immersion spectra of 127 GBM acquisitions, 668 metastatic acquisitions and 157 normal 
brain acquisitions. Spectra have been vector normalised, the backgrounds have been corrected using a 5th order 
polynomial fit and subtraction and 7 points of smoothing. The asterisks correspond to paraffin peaks from 
residual wax in the tissue. 
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Figure 8.  The average intensity and standard deviation of three intense paraffin 
peaks at 1061, 1131 and 1294 cm-1 for the three tissue types; Normal tissue 
(blue), Glioblastoma multiforme (red) and Metastatic brain cancer (green) 
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